Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.
| DrugCom Name |
DrugCom ID |
Component Drug |
Indication |
REF |
|
10-hydroxycamptothecin + SCH-900776
|
DCHRE1S
|
10-hydroxycamptothecin
|
Breast and ovarian cancer syndrome (Cell Line: UWB1289)
|
[2] |
|
10-hydroxycamptothecin + SCH-900776
|
DC8NQQO
|
10-hydroxycamptothecin
|
Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1)
|
[2] |
|
10-hydroxycamptothecin + SCH-900776
|
DCSTISN
|
10-hydroxycamptothecin
|
Adenocarcinoma (Cell Line: CAOV3)
|
[3] |
|
10-hydroxycamptothecin + SCH-900776
|
DCNHJHZ
|
10-hydroxycamptothecin
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[3] |
|
10-hydroxycamptothecin + SCH-900776
|
DCQGMIV
|
10-hydroxycamptothecin
|
Adenocarcinoma (Cell Line: NCIH2122)
|
[3] |
|
10-hydroxycamptothecin + SCH-900776
|
DC91IWK
|
10-hydroxycamptothecin
|
Adenocarcinoma (Cell Line: COLO320DM)
|
[3] |
|
10-hydroxycamptothecin + SCH-900776
|
DCJMOTP
|
10-hydroxycamptothecin
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
10-hydroxycamptothecin + SCH-900776
|
DCF6ISV
|
10-hydroxycamptothecin
|
Amelanotic melanoma (Cell Line: A2058)
|
[3] |
|
10-hydroxycamptothecin + SCH-900776
|
DCKZVU9
|
10-hydroxycamptothecin
|
Germ cell tumour (Cell Line: PA1)
|
[3] |
|
10-hydroxycamptothecin + SCH-900776
|
DCLL2UG
|
10-hydroxycamptothecin
|
Malignant melanoma (Cell Line: A375)
|
[3] |
|
10-hydroxycamptothecin + SCH-900776
|
DCY86O0
|
10-hydroxycamptothecin
|
Malignant melanoma (Cell Line: RPMI7951)
|
[3] |
|
10-hydroxycamptothecin + SCH-900776
|
DCN4BHW
|
10-hydroxycamptothecin
|
Mesothelioma (Cell Line: MSTO)
|
[3] |
|
10-hydroxycamptothecin + SCH-900776
|
DCUDNPU
|
10-hydroxycamptothecin
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[3] |
|
10-hydroxycamptothecin + SCH-900776
|
DCF1JOZ
|
10-hydroxycamptothecin
|
Prostate carcinoma (Cell Line: VCAP)
|
[3] |
|
ABT-263 + SCH-900776
|
DCXBQHP
|
ABT-263
|
Ewing sarcoma (Cell Line: TC-71)
|
[3] |
|
Bortezomib + SCH-900776
|
DC0X7LK
|
Bortezomib
|
Adenocarcinoma (Cell Line: NCIH520)
|
[4] |
|
Bortezomib + SCH-900776
|
DCPF8O1
|
Bortezomib
|
Adenocarcinoma (Cell Line: COLO320DM)
|
[4] |
|
Bortezomib + SCH-900776
|
DCDSJ6X
|
Bortezomib
|
Adenocarcinoma (Cell Line: HCT116)
|
[4] |
|
Bortezomib + SCH-900776
|
DCODT70
|
Bortezomib
|
Amelanotic melanoma (Cell Line: A2058)
|
[4] |
|
Bortezomib + SCH-900776
|
DCB4552
|
Bortezomib
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[4] |
|
Bortezomib + SCH-900776
|
DC8YRTY
|
Bortezomib
|
Ovarian endometrioid adenocarcinoma (Cell Line: A2780)
|
[4] |
|
Cantharidin + SCH-900776
|
DC0D0GA
|
Cantharidin
|
Ewing sarcoma (Cell Line: TC-71)
|
[4] |
|
Cyclophosphamide + SCH-900776
|
DCOBJOZ
|
Cyclophosphamide
|
Adenocarcinoma (Cell Line: SW-620)
|
[4] |
|
Cyclophosphamide + SCH-900776
|
DCK9EJ2
|
Cyclophosphamide
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[2] |
|
Dasatinib + SCH-900776
|
DC83U6D
|
Dasatinib
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[4] |
|
Dasatinib + SCH-900776
|
DCIMXI7
|
Dasatinib
|
Adenocarcinoma (Cell Line: A427)
|
[4] |
|
Dasatinib + SCH-900776
|
DCZRJON
|
Dasatinib
|
Adenocarcinoma (Cell Line: NCIH1650)
|
[4] |
|
Dasatinib + SCH-900776
|
DCTZJLJ
|
Dasatinib
|
Adenocarcinoma (Cell Line: NCIH23)
|
[4] |
|
Dasatinib + SCH-900776
|
DC9179G
|
Dasatinib
|
Adenocarcinoma (Cell Line: NCIH520)
|
[4] |
|
Dasatinib + SCH-900776
|
DCBP533
|
Dasatinib
|
Adenocarcinoma (Cell Line: DLD1)
|
[4] |
|
Dasatinib + SCH-900776
|
DCVO5K2
|
Dasatinib
|
Adenocarcinoma (Cell Line: HCT116)
|
[4] |
|
Dasatinib + SCH-900776
|
DCAFKRT
|
Dasatinib
|
Adenocarcinoma (Cell Line: HT29)
|
[4] |
|
Dasatinib + SCH-900776
|
DCTDXXY
|
Dasatinib
|
Adenocarcinoma (Cell Line: SW-620)
|
[4] |
|
Dasatinib + SCH-900776
|
DC15CBA
|
Dasatinib
|
Amelanotic melanoma (Cell Line: A2058)
|
[4] |
|
Dasatinib + SCH-900776
|
DC7YHAC
|
Dasatinib
|
Germ cell tumour (Cell Line: PA1)
|
[4] |
|
Dasatinib + SCH-900776
|
DC9JYRN
|
Dasatinib
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[4] |
|
Dasatinib + SCH-900776
|
DCKKH4K
|
Dasatinib
|
Malignant melanoma (Cell Line: A375)
|
[4] |
|
Dasatinib + SCH-900776
|
DCRLZTX
|
Dasatinib
|
Malignant melanoma (Cell Line: HT144)
|
[4] |
|
Dasatinib + SCH-900776
|
DCUPE08
|
Dasatinib
|
Malignant melanoma (Cell Line: RPMI7951)
|
[4] |
|
Dasatinib + SCH-900776
|
DCRM1ML
|
Dasatinib
|
Malignant melanoma (Cell Line: UACC62)
|
[4] |
|
Dasatinib + SCH-900776
|
DCZNUF7
|
Dasatinib
|
Mesothelioma (Cell Line: MSTO)
|
[4] |
|
Dasatinib + SCH-900776
|
DCVZKCG
|
Dasatinib
|
Non small cell carcinoma (Cell Line: SKMES1)
|
[4] |
|
Dasatinib + SCH-900776
|
DCFC4EK
|
Dasatinib
|
Ovarian endometrioid adenocarcinoma (Cell Line: A2780)
|
[4] |
|
Dasatinib + SCH-900776
|
DC1HGCW
|
Dasatinib
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[4] |
|
Dasatinib + SCH-900776
|
DCSN5X9
|
Dasatinib
|
Prostate carcinoma (Cell Line: VCAP)
|
[4] |
|
Dasatinib + SCH-900776
|
DCIFJUZ
|
Dasatinib
|
Breast carcinoma (Cell Line: KPL1)
|
[2] |
|
Dasatinib + SCH-900776
|
DCJKEC5
|
Dasatinib
|
Breast carcinoma (Cell Line: OCUBM)
|
[2] |
|
Dasatinib + SCH-900776
|
DC7O2QQ
|
Dasatinib
|
Carcinoma (Cell Line: OV90)
|
[2] |
|
Dasatinib + SCH-900776
|
DCPLBS2
|
Dasatinib
|
Carcinoma (Cell Line: EFM192B)
|
[2] |
|
Dasatinib + SCH-900776
|
DCCES8B
|
Dasatinib
|
Carcinoma (Cell Line: MDAMB436)
|
[2] |
|
Dasatinib + SCH-900776
|
DC18BU6
|
Dasatinib
|
Colon adenocarcinoma (Cell Line: LOVO)
|
[2] |
|
Dasatinib + SCH-900776
|
DCTOVGO
|
Dasatinib
|
Colon carcinoma (Cell Line: RKO)
|
[2] |
|
Dasatinib + SCH-900776
|
DCO3ZBC
|
Dasatinib
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[2] |
|
Dasatinib + SCH-900776
|
DC7VTUM
|
Dasatinib
|
Rectal adenocarcinoma (Cell Line: SW837)
|
[2] |
|
Dexamethasone + SCH-900776
|
DC0VBLG
|
Dexamethasone
|
Breast carcinoma (Cell Line: KPL1)
|
[2] |
|
Dexamethasone + SCH-900776
|
DC4H5TR
|
Dexamethasone
|
Breast carcinoma (Cell Line: OCUBM)
|
[2] |
|
Dexamethasone + SCH-900776
|
DC1K6QJ
|
Dexamethasone
|
Colon adenocarcinoma (Cell Line: LOVO)
|
[2] |
|
Dexamethasone + SCH-900776
|
DCB6NYP
|
Dexamethasone
|
Adenocarcinoma (Cell Line: CAOV3)
|
[3] |
|
Dexamethasone + SCH-900776
|
DCF3HD1
|
Dexamethasone
|
Adenocarcinoma (Cell Line: DLD1)
|
[3] |
|
Dexamethasone + SCH-900776
|
DCR3GDK
|
Dexamethasone
|
Adenocarcinoma (Cell Line: SW-620)
|
[3] |
|
Dexamethasone + SCH-900776
|
DCHF3OM
|
Dexamethasone
|
Germ cell tumour (Cell Line: PA1)
|
[3] |
|
Dexamethasone + SCH-900776
|
DC26MDL
|
Dexamethasone
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
Doxorubicin + SCH-900776
|
DCVNOFB
|
Doxorubicin
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[4] |
|
Doxorubicin + SCH-900776
|
DC5GYKZ
|
Doxorubicin
|
Adenocarcinoma (Cell Line: NCIH1650)
|
[4] |
|
Doxorubicin + SCH-900776
|
DCA04ZC
|
Doxorubicin
|
Adenocarcinoma (Cell Line: NCIH520)
|
[4] |
|
Doxorubicin + SCH-900776
|
DCR3WPD
|
Doxorubicin
|
Adenocarcinoma (Cell Line: COLO320DM)
|
[4] |
|
Doxorubicin + SCH-900776
|
DCCPA86
|
Doxorubicin
|
Adenocarcinoma (Cell Line: DLD1)
|
[4] |
|
Doxorubicin + SCH-900776
|
DCACY3H
|
Doxorubicin
|
Adenocarcinoma (Cell Line: HT29)
|
[4] |
|
Doxorubicin + SCH-900776
|
DCY29RX
|
Doxorubicin
|
Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2)
|
[4] |
|
Doxorubicin + SCH-900776
|
DCORGDA
|
Doxorubicin
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[4] |
|
Doxorubicin + SCH-900776
|
DCQIN79
|
Doxorubicin
|
Malignant melanoma (Cell Line: RPMI7951)
|
[4] |
|
Doxorubicin + SCH-900776
|
DCMBUCP
|
Doxorubicin
|
Malignant melanoma (Cell Line: SKMEL30)
|
[4] |
|
Doxorubicin + SCH-900776
|
DCEO81I
|
Doxorubicin
|
Mesothelioma (Cell Line: MSTO)
|
[4] |
|
Doxorubicin + SCH-900776
|
DCR5G9Y
|
Doxorubicin
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[4] |
|
Doxorubicin + SCH-900776
|
DCY6SEL
|
Doxorubicin
|
Breast and ovarian cancer syndrome (Cell Line: UWB1289)
|
[2] |
|
Doxorubicin + SCH-900776
|
DCCVD13
|
Doxorubicin
|
Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1)
|
[2] |
|
Erlotinib + SCH-900776
|
DCF8BZU
|
Erlotinib
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[4] |
|
Erlotinib + SCH-900776
|
DCTTDP0
|
Erlotinib
|
Adenocarcinoma (Cell Line: CAOV3)
|
[4] |
|
Erlotinib + SCH-900776
|
DC2XL6A
|
Erlotinib
|
Adenocarcinoma (Cell Line: A427)
|
[4] |
|
Erlotinib + SCH-900776
|
DCIKKKF
|
Erlotinib
|
Adenocarcinoma (Cell Line: NCIH2122)
|
[4] |
|
Erlotinib + SCH-900776
|
DCU81XR
|
Erlotinib
|
Adenocarcinoma (Cell Line: NCIH23)
|
[4] |
|
Erlotinib + SCH-900776
|
DCXFE85
|
Erlotinib
|
Adenocarcinoma (Cell Line: NCIH520)
|
[4] |
|
Erlotinib + SCH-900776
|
DCKX7YD
|
Erlotinib
|
Adenocarcinoma (Cell Line: COLO320DM)
|
[4] |
|
Erlotinib + SCH-900776
|
DCX7EJU
|
Erlotinib
|
Adenocarcinoma (Cell Line: DLD1)
|
[4] |
|
Erlotinib + SCH-900776
|
DCKOTM9
|
Erlotinib
|
Adenocarcinoma (Cell Line: HT29)
|
[4] |
|
Erlotinib + SCH-900776
|
DCQ2UF3
|
Erlotinib
|
Adenocarcinoma (Cell Line: SW-620)
|
[4] |
|
Erlotinib + SCH-900776
|
DC9GKCF
|
Erlotinib
|
Adenocarcinoma (Cell Line: HCT116)
|
[4] |
|
Erlotinib + SCH-900776
|
DCVPQTS
|
Erlotinib
|
Amelanotic melanoma (Cell Line: A2058)
|
[4] |
|
Erlotinib + SCH-900776
|
DC7UZV4
|
Erlotinib
|
Germ cell tumour (Cell Line: PA1)
|
[4] |
|
Erlotinib + SCH-900776
|
DCEKLJP
|
Erlotinib
|
Malignant melanoma (Cell Line: HT144)
|
[4] |
|
Erlotinib + SCH-900776
|
DCXLZSI
|
Erlotinib
|
Malignant melanoma (Cell Line: RPMI7951)
|
[4] |
|
Erlotinib + SCH-900776
|
DCW6E16
|
Erlotinib
|
Malignant melanoma (Cell Line: SKMEL30)
|
[4] |
|
Erlotinib + SCH-900776
|
DCA2ZYO
|
Erlotinib
|
Malignant melanoma (Cell Line: UACC62)
|
[4] |
|
Erlotinib + SCH-900776
|
DCP2AOX
|
Erlotinib
|
Malignant melanoma (Cell Line: A375)
|
[4] |
|
Erlotinib + SCH-900776
|
DCXZ5EZ
|
Erlotinib
|
Mesothelioma (Cell Line: MSTO)
|
[4] |
|
Erlotinib + SCH-900776
|
DCTS95G
|
Erlotinib
|
Non small cell carcinoma (Cell Line: SKMES1)
|
[4] |
|
Erlotinib + SCH-900776
|
DC0OQIR
|
Erlotinib
|
Ovarian endometrioid adenocarcinoma (Cell Line: A2780)
|
[4] |
|
Erlotinib + SCH-900776
|
DCXIX79
|
Erlotinib
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[4] |
|
Erlotinib + SCH-900776
|
DCNLBJK
|
Erlotinib
|
Prostate carcinoma (Cell Line: LNCAP)
|
[4] |
|
Erlotinib + SCH-900776
|
DCMBPBM
|
Erlotinib
|
Carcinoma (Cell Line: OV90)
|
[2] |
|
Erlotinib + SCH-900776
|
DCK7YBM
|
Erlotinib
|
Carcinoma (Cell Line: EFM192B)
|
[2] |
|
Erlotinib + SCH-900776
|
DCE0BDL
|
Erlotinib
|
Rectal adenocarcinoma (Cell Line: SW837)
|
[2] |
|
Estramustine + SCH-900776
|
DCKJ8Q5
|
Estramustine
|
Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2)
|
[4] |
|
Estramustine + SCH-900776
|
DCZQZ8O
|
Estramustine
|
Breast and ovarian cancer syndrome (Cell Line: UWB1289)
|
[2] |
|
Estramustine + SCH-900776
|
DC6PA6A
|
Estramustine
|
Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1)
|
[2] |
|
Estramustine + SCH-900776
|
DCMVT6M
|
Estramustine
|
Breast carcinoma (Cell Line: KPL1)
|
[2] |
|
Estramustine + SCH-900776
|
DCTOA3M
|
Estramustine
|
Breast carcinoma (Cell Line: OCUBM)
|
[2] |
|
Estramustine + SCH-900776
|
DCD8FR0
|
Estramustine
|
Carcinoma (Cell Line: OV90)
|
[2] |
|
Estramustine + SCH-900776
|
DCVAV01
|
Estramustine
|
Carcinoma (Cell Line: EFM192B)
|
[2] |
|
Estramustine + SCH-900776
|
DCH7NKT
|
Estramustine
|
Carcinoma (Cell Line: MDAMB436)
|
[2] |
|
Estramustine + SCH-900776
|
DCGL4IA
|
Estramustine
|
Colon adenocarcinoma (Cell Line: LOVO)
|
[2] |
|
Estramustine + SCH-900776
|
DCYEI30
|
Estramustine
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[2] |
|
Estramustine + SCH-900776
|
DCVOP7Q
|
Estramustine
|
Adenocarcinoma (Cell Line: CAOV3)
|
[3] |
|
Estramustine + SCH-900776
|
DC12K7A
|
Estramustine
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[3] |
|
Estramustine + SCH-900776
|
DCGWSD1
|
Estramustine
|
Adenocarcinoma (Cell Line: NCIH23)
|
[3] |
|
Estramustine + SCH-900776
|
DCODMCR
|
Estramustine
|
Adenocarcinoma (Cell Line: NCIH520)
|
[3] |
|
Estramustine + SCH-900776
|
DCASNHG
|
Estramustine
|
Adenocarcinoma (Cell Line: COLO320DM)
|
[3] |
|
Estramustine + SCH-900776
|
DC8NXMH
|
Estramustine
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
Estramustine + SCH-900776
|
DC8KCAR
|
Estramustine
|
Amelanotic melanoma (Cell Line: A2058)
|
[3] |
|
Estramustine + SCH-900776
|
DCHN4GA
|
Estramustine
|
Germ cell tumour (Cell Line: PA1)
|
[3] |
|
Estramustine + SCH-900776
|
DCBXIRD
|
Estramustine
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
Estramustine + SCH-900776
|
DC9MSVH
|
Estramustine
|
Malignant melanoma (Cell Line: A375)
|
[3] |
|
Estramustine + SCH-900776
|
DCVGC4Q
|
Estramustine
|
Malignant melanoma (Cell Line: HT144)
|
[3] |
|
Estramustine + SCH-900776
|
DCV6X24
|
Estramustine
|
Malignant melanoma (Cell Line: RPMI7951)
|
[3] |
|
Estramustine + SCH-900776
|
DCBSU7P
|
Estramustine
|
Malignant melanoma (Cell Line: SKMEL30)
|
[3] |
|
Estramustine + SCH-900776
|
DCHM2QK
|
Estramustine
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
Estramustine + SCH-900776
|
DC5PIBS
|
Estramustine
|
Mesothelioma (Cell Line: MSTO)
|
[3] |
|
Estramustine + SCH-900776
|
DC47NSK
|
Estramustine
|
Non small cell carcinoma (Cell Line: SKMES1)
|
[3] |
|
Estramustine + SCH-900776
|
DCQOYSF
|
Estramustine
|
Ovarian endometrioid adenocarcinoma (Cell Line: A2780)
|
[3] |
|
Estramustine + SCH-900776
|
DC1XDU9
|
Estramustine
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[3] |
|
Etoposide + SCH-900776
|
DC897PH
|
Etoposide
|
Adenocarcinoma (Cell Line: CAOV3)
|
[4] |
|
Etoposide + SCH-900776
|
DCPJKPX
|
Etoposide
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[4] |
|
Etoposide + SCH-900776
|
DCH0785
|
Etoposide
|
Adenocarcinoma (Cell Line: NCIH1650)
|
[4] |
|
Etoposide + SCH-900776
|
DCIGISI
|
Etoposide
|
Adenocarcinoma (Cell Line: NCIH2122)
|
[4] |
|
Etoposide + SCH-900776
|
DCEKAFX
|
Etoposide
|
Adenocarcinoma (Cell Line: NCIH23)
|
[4] |
|
Etoposide + SCH-900776
|
DC6DWMH
|
Etoposide
|
Adenocarcinoma (Cell Line: NCIH520)
|
[4] |
|
Etoposide + SCH-900776
|
DCHTPZ9
|
Etoposide
|
Adenocarcinoma (Cell Line: COLO320DM)
|
[4] |
|
Etoposide + SCH-900776
|
DC7Z4V3
|
Etoposide
|
Adenocarcinoma (Cell Line: DLD1)
|
[4] |
|
Etoposide + SCH-900776
|
DC5UOTV
|
Etoposide
|
Adenocarcinoma (Cell Line: HCT116)
|
[4] |
|
Etoposide + SCH-900776
|
DC8TUFA
|
Etoposide
|
Adenocarcinoma (Cell Line: HT29)
|
[4] |
|
Etoposide + SCH-900776
|
DCZHJXN
|
Etoposide
|
Amelanotic melanoma (Cell Line: A2058)
|
[4] |
|
Etoposide + SCH-900776
|
DCW57HO
|
Etoposide
|
Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2)
|
[4] |
|
Etoposide + SCH-900776
|
DCY2PYG
|
Etoposide
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[4] |
|
Etoposide + SCH-900776
|
DCVUKR5
|
Etoposide
|
Malignant melanoma (Cell Line: HT144)
|
[4] |
|
Etoposide + SCH-900776
|
DCPPP23
|
Etoposide
|
Malignant melanoma (Cell Line: RPMI7951)
|
[4] |
|
Etoposide + SCH-900776
|
DCPCXD8
|
Etoposide
|
Malignant melanoma (Cell Line: SKMEL30)
|
[4] |
|
Etoposide + SCH-900776
|
DCZZUXM
|
Etoposide
|
Malignant melanoma (Cell Line: UACC62)
|
[4] |
|
Etoposide + SCH-900776
|
DCIEBDC
|
Etoposide
|
Mesothelioma (Cell Line: MSTO)
|
[4] |
|
Etoposide + SCH-900776
|
DCJV1CM
|
Etoposide
|
Ovarian endometrioid adenocarcinoma (Cell Line: A2780)
|
[4] |
|
Etoposide + SCH-900776
|
DC9H87F
|
Etoposide
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[4] |
|
Etoposide + SCH-900776
|
DCNMLOI
|
Etoposide
|
Prostate carcinoma (Cell Line: LNCAP)
|
[4] |
|
Etoposide + SCH-900776
|
DCEL9DT
|
Etoposide
|
Prostate carcinoma (Cell Line: VCAP)
|
[4] |
|
Etoposide + SCH-900776
|
DC2ACXA
|
Etoposide
|
Breast and ovarian cancer syndrome (Cell Line: UWB1289)
|
[2] |
|
Etoposide + SCH-900776
|
DCV1S66
|
Etoposide
|
Breast carcinoma (Cell Line: KPL1)
|
[2] |
|
Etoposide + SCH-900776
|
DCTCQSY
|
Etoposide
|
Carcinoma (Cell Line: OV90)
|
[2] |
|
Etoposide + SCH-900776
|
DCYRD3S
|
Etoposide
|
Carcinoma (Cell Line: EFM192B)
|
[2] |
|
Etoposide + SCH-900776
|
DC0K7YD
|
Etoposide
|
Colon adenocarcinoma (Cell Line: LOVO)
|
[2] |
|
Etoposide + SCH-900776
|
DC6GKKK
|
Etoposide
|
Colon carcinoma (Cell Line: RKO)
|
[2] |
|
Etoposide + SCH-900776
|
DCU7WG2
|
Etoposide
|
Rectal adenocarcinoma (Cell Line: SW837)
|
[2] |
|
Fluorouracil + SCH-900776
|
DC9MNFP
|
Fluorouracil
|
Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2)
|
[4] |
|
Fluorouracil + SCH-900776
|
DCUEXMJ
|
Fluorouracil
|
Breast and ovarian cancer syndrome (Cell Line: UWB1289)
|
[2] |
|
Fluorouracil + SCH-900776
|
DCWJWRH
|
Fluorouracil
|
Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1)
|
[2] |
|
Fluorouracil + SCH-900776
|
DCVG2RL
|
Fluorouracil
|
Breast carcinoma (Cell Line: OCUBM)
|
[2] |
|
Fluorouracil + SCH-900776
|
DCUP3WX
|
Fluorouracil
|
Carcinoma (Cell Line: OV90)
|
[2] |
|
Fluorouracil + SCH-900776
|
DCLL34N
|
Fluorouracil
|
Carcinoma (Cell Line: EFM192B)
|
[2] |
|
Fluorouracil + SCH-900776
|
DCOUDM4
|
Fluorouracil
|
Colon adenocarcinoma (Cell Line: LOVO)
|
[2] |
|
Fluorouracil + SCH-900776
|
DCBJGZ2
|
Fluorouracil
|
Colon carcinoma (Cell Line: RKO)
|
[2] |
|
Fluorouracil + SCH-900776
|
DCZ32VP
|
Fluorouracil
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[2] |
|
Fluorouracil + SCH-900776
|
DCRMG4Y
|
Fluorouracil
|
Adenocarcinoma (Cell Line: CAOV3)
|
[3] |
|
Fluorouracil + SCH-900776
|
DCS0473
|
Fluorouracil
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[3] |
|
Fluorouracil + SCH-900776
|
DCYN63P
|
Fluorouracil
|
Adenocarcinoma (Cell Line: A427)
|
[3] |
|
Fluorouracil + SCH-900776
|
DC6MPZJ
|
Fluorouracil
|
Adenocarcinoma (Cell Line: NCIH1650)
|
[3] |
|
Fluorouracil + SCH-900776
|
DCL2671
|
Fluorouracil
|
Adenocarcinoma (Cell Line: NCIH2122)
|
[3] |
|
Fluorouracil + SCH-900776
|
DCS3HUI
|
Fluorouracil
|
Adenocarcinoma (Cell Line: NCIH23)
|
[3] |
|
Fluorouracil + SCH-900776
|
DC2QNN5
|
Fluorouracil
|
Adenocarcinoma (Cell Line: NCIH520)
|
[3] |
|
Fluorouracil + SCH-900776
|
DCV3SUT
|
Fluorouracil
|
Adenocarcinoma (Cell Line: COLO320DM)
|
[3] |
|
Fluorouracil + SCH-900776
|
DCSGNF4
|
Fluorouracil
|
Adenocarcinoma (Cell Line: HCT116)
|
[3] |
|
Fluorouracil + SCH-900776
|
DC767LN
|
Fluorouracil
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
Fluorouracil + SCH-900776
|
DCP8QBU
|
Fluorouracil
|
Adenocarcinoma (Cell Line: SW-620)
|
[3] |
|
Fluorouracil + SCH-900776
|
DC4IO3Q
|
Fluorouracil
|
Germ cell tumour (Cell Line: PA1)
|
[3] |
|
Fluorouracil + SCH-900776
|
DCOFHPJ
|
Fluorouracil
|
Malignant melanoma (Cell Line: A375)
|
[3] |
|
Fluorouracil + SCH-900776
|
DCKWYOV
|
Fluorouracil
|
Malignant melanoma (Cell Line: RPMI7951)
|
[3] |
|
Fluorouracil + SCH-900776
|
DCNCE0A
|
Fluorouracil
|
Malignant melanoma (Cell Line: SKMEL30)
|
[3] |
|
Fluorouracil + SCH-900776
|
DCVBV2H
|
Fluorouracil
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
Fluorouracil + SCH-900776
|
DCLF6OC
|
Fluorouracil
|
Non small cell carcinoma (Cell Line: SKMES1)
|
[3] |
|
Fluorouracil + SCH-900776
|
DCUAKX2
|
Fluorouracil
|
Ovarian endometrioid adenocarcinoma (Cell Line: A2780)
|
[3] |
|
Fluorouracil + SCH-900776
|
DC566F3
|
Fluorouracil
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[3] |
|
Fluorouracil + SCH-900776
|
DCDOPFF
|
Fluorouracil
|
Prostate carcinoma (Cell Line: VCAP)
|
[3] |
|
Gemcitabine + SCH-900776
|
DCA7BPX
|
Gemcitabine
|
Adenocarcinoma (Cell Line: CAOV3)
|
[4] |
|
Gemcitabine + SCH-900776
|
DC6SQEX
|
Gemcitabine
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[4] |
|
Gemcitabine + SCH-900776
|
DCHNTC2
|
Gemcitabine
|
Adenocarcinoma (Cell Line: A427)
|
[4] |
|
Gemcitabine + SCH-900776
|
DCI40AC
|
Gemcitabine
|
Adenocarcinoma (Cell Line: NCIH1650)
|
[4] |
|
Gemcitabine + SCH-900776
|
DCRAZV5
|
Gemcitabine
|
Adenocarcinoma (Cell Line: NCIH2122)
|
[4] |
|
Gemcitabine + SCH-900776
|
DCMDXDY
|
Gemcitabine
|
Adenocarcinoma (Cell Line: NCIH23)
|
[4] |
|
Gemcitabine + SCH-900776
|
DCEMQ57
|
Gemcitabine
|
Adenocarcinoma (Cell Line: NCIH520)
|
[4] |
|
Gemcitabine + SCH-900776
|
DC7A0NJ
|
Gemcitabine
|
Adenocarcinoma (Cell Line: COLO320DM)
|
[4] |
|
Gemcitabine + SCH-900776
|
DC7HWO9
|
Gemcitabine
|
Adenocarcinoma (Cell Line: DLD1)
|
[4] |
|
Gemcitabine + SCH-900776
|
DCMEAFV
|
Gemcitabine
|
Adenocarcinoma (Cell Line: HT29)
|
[4] |
|
Gemcitabine + SCH-900776
|
DCG1H5Y
|
Gemcitabine
|
Adenocarcinoma (Cell Line: SW-620)
|
[4] |
|
Gemcitabine + SCH-900776
|
DC27FNX
|
Gemcitabine
|
Adenocarcinoma (Cell Line: HCT116)
|
[4] |
|
Gemcitabine + SCH-900776
|
DCMSYLS
|
Gemcitabine
|
Amelanotic melanoma (Cell Line: A2058)
|
[4] |
|
Gemcitabine + SCH-900776
|
DC4C4MK
|
Gemcitabine
|
Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2)
|
[4] |
|
Gemcitabine + SCH-900776
|
DCM5CK1
|
Gemcitabine
|
Germ cell tumour (Cell Line: PA1)
|
[4] |
|
Gemcitabine + SCH-900776
|
DCXV3MY
|
Gemcitabine
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[4] |
|
Gemcitabine + SCH-900776
|
DCWTVMY
|
Gemcitabine
|
Malignant melanoma (Cell Line: HT144)
|
[4] |
|
Gemcitabine + SCH-900776
|
DC8JB9U
|
Gemcitabine
|
Malignant melanoma (Cell Line: RPMI7951)
|
[4] |
|
Gemcitabine + SCH-900776
|
DC8DSR2
|
Gemcitabine
|
Malignant melanoma (Cell Line: SKMEL30)
|
[4] |
|
Gemcitabine + SCH-900776
|
DCH60LK
|
Gemcitabine
|
Malignant melanoma (Cell Line: UACC62)
|
[4] |
|
Gemcitabine + SCH-900776
|
DC99DAI
|
Gemcitabine
|
Malignant melanoma (Cell Line: A375)
|
[4] |
|
Gemcitabine + SCH-900776
|
DC6XN1G
|
Gemcitabine
|
Mesothelioma (Cell Line: MSTO)
|
[4] |
|
Gemcitabine + SCH-900776
|
DCKYSBK
|
Gemcitabine
|
Ovarian endometrioid adenocarcinoma (Cell Line: A2780)
|
[4] |
|
Gemcitabine + SCH-900776
|
DC88RCK
|
Gemcitabine
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[4] |
|
Gemcitabine + SCH-900776
|
DCOA8LO
|
Gemcitabine
|
Prostate carcinoma (Cell Line: LNCAP)
|
[4] |
|
Gemcitabine + SCH-900776
|
DCDT16R
|
Gemcitabine
|
Prostate carcinoma (Cell Line: VCAP)
|
[4] |
|
Gemcitabine + SCH-900776
|
DC1R3A5
|
Gemcitabine
|
Breast and ovarian cancer syndrome (Cell Line: UWB1289)
|
[2] |
|
Gemcitabine + SCH-900776
|
DCJ19QK
|
Gemcitabine
|
Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1)
|
[2] |
|
Gemcitabine + SCH-900776
|
DC5U3WA
|
Gemcitabine
|
Breast carcinoma (Cell Line: OCUBM)
|
[2] |
|
Gemcitabine + SCH-900776
|
DCINX8I
|
Gemcitabine
|
Carcinoma (Cell Line: MDAMB436)
|
[2] |
|
Gemcitabine + SCH-900776
|
DCZIMSV
|
Gemcitabine
|
Colon adenocarcinoma (Cell Line: LOVO)
|
[2] |
|
Gemcitabine + SCH-900776
|
DCI1KBE
|
Gemcitabine
|
Colon carcinoma (Cell Line: RKO)
|
[2] |
|
Gemcitabine + SCH-900776
|
DCIMMMU
|
Gemcitabine
|
Rectal adenocarcinoma (Cell Line: SW837)
|
[2] |
|
GSK525762 + SCH-900776
|
DC827FI
|
GSK525762
|
Carcinoma (Cell Line: MDAMB436)
|
[2] |
|
GSK525762 + SCH-900776
|
DC5FMR9
|
GSK525762
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[2] |
|
GSK525762 + SCH-900776
|
DC7FMHF
|
GSK525762
|
Adenocarcinoma (Cell Line: COLO320DM)
|
[3] |
|
GSK525762 + SCH-900776
|
DCGK8F8
|
GSK525762
|
Adenocarcinoma (Cell Line: SW-620)
|
[3] |
|
GSK525762 + SCH-900776
|
DCZM1RY
|
GSK525762
|
Mesothelioma (Cell Line: MSTO)
|
[3] |
|
GSK525762 + SCH-900776
|
DCPYA84
|
GSK525762
|
Ovarian endometrioid adenocarcinoma (Cell Line: A2780)
|
[3] |
|
Idarubicin + SCH-900776
|
DC3PZDU
|
Idarubicin
|
Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2)
|
[4] |
|
Idarubicin + SCH-900776
|
DCVVTQA
|
Idarubicin
|
Carcinoma (Cell Line: OV90)
|
[2] |
|
Idarubicin + SCH-900776
|
DCPK21J
|
Idarubicin
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[2] |
|
Idarubicin + SCH-900776
|
DC79XNT
|
Idarubicin
|
Adenocarcinoma (Cell Line: CAOV3)
|
[3] |
|
Idarubicin + SCH-900776
|
DCZ5OCC
|
Idarubicin
|
Adenocarcinoma (Cell Line: A427)
|
[3] |
|
Idarubicin + SCH-900776
|
DCZLE36
|
Idarubicin
|
Adenocarcinoma (Cell Line: NCIH2122)
|
[3] |
|
Idarubicin + SCH-900776
|
DCRV2EX
|
Idarubicin
|
Adenocarcinoma (Cell Line: COLO320DM)
|
[3] |
|
Idarubicin + SCH-900776
|
DCF3RFV
|
Idarubicin
|
Adenocarcinoma (Cell Line: SW-620)
|
[3] |
|
Idarubicin + SCH-900776
|
DCOX8DV
|
Idarubicin
|
Amelanotic melanoma (Cell Line: A2058)
|
[3] |
|
Idarubicin + SCH-900776
|
DCL7PM8
|
Idarubicin
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
Idarubicin + SCH-900776
|
DCW1PG6
|
Idarubicin
|
Malignant melanoma (Cell Line: A375)
|
[3] |
|
Idarubicin + SCH-900776
|
DCRNMQK
|
Idarubicin
|
Malignant melanoma (Cell Line: RPMI7951)
|
[3] |
|
Idarubicin + SCH-900776
|
DCEH6JU
|
Idarubicin
|
Malignant melanoma (Cell Line: SKMEL30)
|
[3] |
|
Idarubicin + SCH-900776
|
DCR9N5N
|
Idarubicin
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
Idarubicin + SCH-900776
|
DC3S21B
|
Idarubicin
|
Mesothelioma (Cell Line: MSTO)
|
[3] |
|
Idarubicin + SCH-900776
|
DCHAX3W
|
Idarubicin
|
Ovarian endometrioid adenocarcinoma (Cell Line: A2780)
|
[3] |
|
Lapatinib + SCH-900776
|
DCCLPD0
|
Lapatinib
|
Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1)
|
[2] |
|
Lapatinib + SCH-900776
|
DCCZ72M
|
Lapatinib
|
Breast carcinoma (Cell Line: KPL1)
|
[2] |
|
Lapatinib + SCH-900776
|
DC3V4IY
|
Lapatinib
|
Breast carcinoma (Cell Line: OCUBM)
|
[2] |
|
Lapatinib + SCH-900776
|
DCVPY1B
|
Lapatinib
|
Carcinoma (Cell Line: EFM192B)
|
[2] |
|
Lapatinib + SCH-900776
|
DCXKUTJ
|
Lapatinib
|
Carcinoma (Cell Line: MDAMB436)
|
[2] |
|
Lapatinib + SCH-900776
|
DCJ6ADC
|
Lapatinib
|
Colon adenocarcinoma (Cell Line: LOVO)
|
[2] |
|
Lapatinib + SCH-900776
|
DCYN8E6
|
Lapatinib
|
Colon carcinoma (Cell Line: RKO)
|
[2] |
|
Lapatinib + SCH-900776
|
DCVQ0S3
|
Lapatinib
|
Rectal adenocarcinoma (Cell Line: SW837)
|
[2] |
|
Lapatinib + SCH-900776
|
DCPRZL1
|
Lapatinib
|
Adenocarcinoma (Cell Line: CAOV3)
|
[3] |
|
Lapatinib + SCH-900776
|
DC4UVY1
|
Lapatinib
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[3] |
|
Lapatinib + SCH-900776
|
DCIJHN8
|
Lapatinib
|
Adenocarcinoma (Cell Line: A427)
|
[3] |
|
Lapatinib + SCH-900776
|
DC7NQHO
|
Lapatinib
|
Adenocarcinoma (Cell Line: NCIH2122)
|
[3] |
|
Lapatinib + SCH-900776
|
DC7KLHI
|
Lapatinib
|
Adenocarcinoma (Cell Line: NCIH23)
|
[3] |
|
Lapatinib + SCH-900776
|
DCWTFQ8
|
Lapatinib
|
Adenocarcinoma (Cell Line: COLO320DM)
|
[3] |
|
Lapatinib + SCH-900776
|
DCPHQOE
|
Lapatinib
|
Adenocarcinoma (Cell Line: DLD1)
|
[3] |
|
Lapatinib + SCH-900776
|
DC7UJ88
|
Lapatinib
|
Adenocarcinoma (Cell Line: HCT116)
|
[3] |
|
Lapatinib + SCH-900776
|
DCV8M0G
|
Lapatinib
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
Lapatinib + SCH-900776
|
DCYVBUC
|
Lapatinib
|
Adenocarcinoma (Cell Line: SW-620)
|
[3] |
|
Lapatinib + SCH-900776
|
DC34WMZ
|
Lapatinib
|
Amelanotic melanoma (Cell Line: A2058)
|
[3] |
|
Lapatinib + SCH-900776
|
DC67BV5
|
Lapatinib
|
Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2)
|
[3] |
|
Lapatinib + SCH-900776
|
DCROA3T
|
Lapatinib
|
Germ cell tumour (Cell Line: PA1)
|
[3] |
|
Lapatinib + SCH-900776
|
DCW9V02
|
Lapatinib
|
Malignant melanoma (Cell Line: A375)
|
[3] |
|
Lapatinib + SCH-900776
|
DCA7DTL
|
Lapatinib
|
Malignant melanoma (Cell Line: HT144)
|
[3] |
|
Lapatinib + SCH-900776
|
DC90EQ2
|
Lapatinib
|
Malignant melanoma (Cell Line: RPMI7951)
|
[3] |
|
Lapatinib + SCH-900776
|
DC0J01A
|
Lapatinib
|
Malignant melanoma (Cell Line: SKMEL30)
|
[3] |
|
Lapatinib + SCH-900776
|
DCU8MEA
|
Lapatinib
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
Lapatinib + SCH-900776
|
DCASJ1H
|
Lapatinib
|
Mesothelioma (Cell Line: MSTO)
|
[3] |
|
Lapatinib + SCH-900776
|
DCG2N6S
|
Lapatinib
|
Non small cell carcinoma (Cell Line: SKMES1)
|
[3] |
|
Lapatinib + SCH-900776
|
DCNC1ZV
|
Lapatinib
|
Ovarian endometrioid adenocarcinoma (Cell Line: A2780)
|
[3] |
|
Lapatinib + SCH-900776
|
DCOCDIM
|
Lapatinib
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[3] |
|
Lapatinib + SCH-900776
|
DCRWOTM
|
Lapatinib
|
Prostate carcinoma (Cell Line: LNCAP)
|
[3] |
|
Lapatinib + SCH-900776
|
DCAQIEP
|
Lapatinib
|
Prostate carcinoma (Cell Line: VCAP)
|
[3] |
|
Lomustine + SCH-900776
|
DC3YOTX
|
Lomustine
|
Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1)
|
[2] |
|
Lomustine + SCH-900776
|
DCGKLP4
|
Lomustine
|
Breast carcinoma (Cell Line: KPL1)
|
[2] |
|
Lomustine + SCH-900776
|
DCK0390
|
Lomustine
|
Breast carcinoma (Cell Line: OCUBM)
|
[2] |
|
Lomustine + SCH-900776
|
DCMFRHQ
|
Lomustine
|
Colon carcinoma (Cell Line: RKO)
|
[2] |
|
Lomustine + SCH-900776
|
DC3BV33
|
Lomustine
|
Adenocarcinoma (Cell Line: CAOV3)
|
[3] |
|
Lomustine + SCH-900776
|
DC2EPM7
|
Lomustine
|
Adenocarcinoma (Cell Line: A427)
|
[3] |
|
Lomustine + SCH-900776
|
DC1BEJC
|
Lomustine
|
Adenocarcinoma (Cell Line: NCIH1650)
|
[3] |
|
Lomustine + SCH-900776
|
DCN2YBN
|
Lomustine
|
Adenocarcinoma (Cell Line: NCIH2122)
|
[3] |
|
Lomustine + SCH-900776
|
DC45KXH
|
Lomustine
|
Adenocarcinoma (Cell Line: NCIH23)
|
[3] |
|
Lomustine + SCH-900776
|
DCX4JWN
|
Lomustine
|
Adenocarcinoma (Cell Line: COLO320DM)
|
[3] |
|
Lomustine + SCH-900776
|
DCEUH1X
|
Lomustine
|
Adenocarcinoma (Cell Line: HCT116)
|
[3] |
|
Lomustine + SCH-900776
|
DC64ASW
|
Lomustine
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
Lomustine + SCH-900776
|
DCUFNLS
|
Lomustine
|
Amelanotic melanoma (Cell Line: A2058)
|
[3] |
|
Lomustine + SCH-900776
|
DCPQB8U
|
Lomustine
|
Malignant melanoma (Cell Line: A375)
|
[3] |
|
Lomustine + SCH-900776
|
DCMPILU
|
Lomustine
|
Malignant melanoma (Cell Line: RPMI7951)
|
[3] |
|
Lomustine + SCH-900776
|
DCE774H
|
Lomustine
|
Malignant melanoma (Cell Line: SKMEL30)
|
[3] |
|
Lomustine + SCH-900776
|
DCVOQCN
|
Lomustine
|
Mesothelioma (Cell Line: MSTO)
|
[3] |
|
Lomustine + SCH-900776
|
DCYWW4F
|
Lomustine
|
Non small cell carcinoma (Cell Line: SKMES1)
|
[3] |
|
Lomustine + SCH-900776
|
DCX0734
|
Lomustine
|
Ovarian endometrioid adenocarcinoma (Cell Line: A2780)
|
[3] |
|
Lomustine + SCH-900776
|
DC2VN67
|
Lomustine
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[3] |
|
Lomustine + SCH-900776
|
DCZGVUP
|
Lomustine
|
Prostate carcinoma (Cell Line: LNCAP)
|
[3] |
|
Metformin + SCH-900776
|
DCKRSR0
|
Metformin
|
Adenocarcinoma (Cell Line: NCIH2122)
|
[4] |
|
Metformin + SCH-900776
|
DCJLVOI
|
Metformin
|
Adenocarcinoma (Cell Line: NCIH520)
|
[4] |
|
Metformin + SCH-900776
|
DCJLXTZ
|
Metformin
|
Adenocarcinoma (Cell Line: HT29)
|
[4] |
|
Metformin + SCH-900776
|
DCFSJ95
|
Metformin
|
Adenocarcinoma (Cell Line: SW-620)
|
[4] |
|
Metformin + SCH-900776
|
DCF0XTR
|
Metformin
|
Malignant melanoma (Cell Line: HT144)
|
[4] |
|
Metformin + SCH-900776
|
DC3R3TU
|
Metformin
|
Prostate carcinoma (Cell Line: LNCAP)
|
[4] |
|
Metformin + SCH-900776
|
DCTDXPS
|
Metformin
|
Breast carcinoma (Cell Line: OCUBM)
|
[2] |
|
Metformin + SCH-900776
|
DCOJW2C
|
Metformin
|
Carcinoma (Cell Line: EFM192B)
|
[2] |
|
Metformin + SCH-900776
|
DC1M9HC
|
Metformin
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[2] |
|
Methotrexate + SCH-900776
|
DCB4GY2
|
Methotrexate
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[4] |
|
Methotrexate + SCH-900776
|
DCRVF6R
|
Methotrexate
|
Adenocarcinoma (Cell Line: NCIH23)
|
[4] |
|
Methotrexate + SCH-900776
|
DCGCF91
|
Methotrexate
|
Ewing sarcoma (Cell Line: TC-71)
|
[4] |
|
Methotrexate + SCH-900776
|
DCPCMK3
|
Methotrexate
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[4] |
|
Methotrexate + SCH-900776
|
DCV3M2S
|
Methotrexate
|
Malignant melanoma (Cell Line: A375)
|
[4] |
|
Methotrexate + SCH-900776
|
DCMYLCC
|
Methotrexate
|
Malignant melanoma (Cell Line: RPMI7951)
|
[4] |
|
Methotrexate + SCH-900776
|
DCKWCI8
|
Methotrexate
|
Mesothelioma (Cell Line: MSTO)
|
[4] |
|
Methotrexate + SCH-900776
|
DCK3GO4
|
Methotrexate
|
Ovarian endometrioid adenocarcinoma (Cell Line: A2780)
|
[4] |
|
Methotrexate + SCH-900776
|
DCKA44C
|
Methotrexate
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[4] |
|
Methotrexate + SCH-900776
|
DC5X33B
|
Methotrexate
|
Carcinoma (Cell Line: EFM192B)
|
[2] |
|
Mitomycin + SCH-900776
|
DCWWTUZ
|
Mitomycin
|
Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2)
|
[4] |
|
Mitomycin + SCH-900776
|
DCKNSXS
|
Mitomycin
|
Breast and ovarian cancer syndrome (Cell Line: UWB1289)
|
[2] |
|
Mitomycin + SCH-900776
|
DCQ8SDD
|
Mitomycin
|
Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1)
|
[2] |
|
Mitomycin + SCH-900776
|
DC3DMYF
|
Mitomycin
|
Breast carcinoma (Cell Line: OCUBM)
|
[2] |
|
Mitomycin + SCH-900776
|
DCDC11P
|
Mitomycin
|
Carcinoma (Cell Line: MDAMB436)
|
[2] |
|
Mitomycin + SCH-900776
|
DCDY965
|
Mitomycin
|
Colon adenocarcinoma (Cell Line: LOVO)
|
[2] |
|
Mitomycin + SCH-900776
|
DCSSTXZ
|
Mitomycin
|
Rectal adenocarcinoma (Cell Line: SW837)
|
[2] |
|
Mitomycin + SCH-900776
|
DCM8M9P
|
Mitomycin
|
Adenocarcinoma (Cell Line: CAOV3)
|
[3] |
|
Mitomycin + SCH-900776
|
DCE6M2R
|
Mitomycin
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[3] |
|
Mitomycin + SCH-900776
|
DC0IWOZ
|
Mitomycin
|
Adenocarcinoma (Cell Line: A427)
|
[3] |
|
Mitomycin + SCH-900776
|
DCQWTEN
|
Mitomycin
|
Adenocarcinoma (Cell Line: NCIH1650)
|
[3] |
|
Mitomycin + SCH-900776
|
DC0VJFT
|
Mitomycin
|
Adenocarcinoma (Cell Line: NCIH2122)
|
[3] |
|
Mitomycin + SCH-900776
|
DC0WWCS
|
Mitomycin
|
Adenocarcinoma (Cell Line: NCIH23)
|
[3] |
|
Mitomycin + SCH-900776
|
DCQO1II
|
Mitomycin
|
Adenocarcinoma (Cell Line: NCIH520)
|
[3] |
|
Mitomycin + SCH-900776
|
DCJZ50T
|
Mitomycin
|
Adenocarcinoma (Cell Line: COLO320DM)
|
[3] |
|
Mitomycin + SCH-900776
|
DCL2REM
|
Mitomycin
|
Adenocarcinoma (Cell Line: DLD1)
|
[3] |
|
Mitomycin + SCH-900776
|
DCQJ7FA
|
Mitomycin
|
Adenocarcinoma (Cell Line: HCT116)
|
[3] |
|
Mitomycin + SCH-900776
|
DCN3Q4A
|
Mitomycin
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
Mitomycin + SCH-900776
|
DCR563N
|
Mitomycin
|
Amelanotic melanoma (Cell Line: A2058)
|
[3] |
|
Mitomycin + SCH-900776
|
DCFAKT0
|
Mitomycin
|
Germ cell tumour (Cell Line: PA1)
|
[3] |
|
Mitomycin + SCH-900776
|
DCAPUX5
|
Mitomycin
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
Mitomycin + SCH-900776
|
DCAMYPR
|
Mitomycin
|
Malignant melanoma (Cell Line: A375)
|
[3] |
|
Mitomycin + SCH-900776
|
DCY1UT9
|
Mitomycin
|
Malignant melanoma (Cell Line: RPMI7951)
|
[3] |
|
Mitomycin + SCH-900776
|
DCPZ84A
|
Mitomycin
|
Malignant melanoma (Cell Line: SKMEL30)
|
[3] |
|
Mitomycin + SCH-900776
|
DC5RXJP
|
Mitomycin
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
Mitomycin + SCH-900776
|
DCH9SQB
|
Mitomycin
|
Mesothelioma (Cell Line: MSTO)
|
[3] |
|
Mitomycin + SCH-900776
|
DCFYHRG
|
Mitomycin
|
Ovarian endometrioid adenocarcinoma (Cell Line: A2780)
|
[3] |
|
Mitomycin + SCH-900776
|
DCMRKLU
|
Mitomycin
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[3] |
|
Mitomycin + SCH-900776
|
DCBIECC
|
Mitomycin
|
Prostate carcinoma (Cell Line: VCAP)
|
[3] |
|
MK-1775 + SCH-900776
|
DC48JJX
|
MK-1775
|
Adenocarcinoma (Cell Line: CAOV3)
|
[4] |
|
MK-1775 + SCH-900776
|
DC230YQ
|
MK-1775
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[4] |
|
MK-1775 + SCH-900776
|
DCG16WG
|
MK-1775
|
Adenocarcinoma (Cell Line: A427)
|
[4] |
|
MK-1775 + SCH-900776
|
DC7VGCL
|
MK-1775
|
Adenocarcinoma (Cell Line: NCIH2122)
|
[4] |
|
MK-1775 + SCH-900776
|
DCYVKW7
|
MK-1775
|
Adenocarcinoma (Cell Line: NCIH520)
|
[4] |
|
MK-1775 + SCH-900776
|
DCTWTOL
|
MK-1775
|
Adenocarcinoma (Cell Line: COLO320DM)
|
[4] |
|
MK-1775 + SCH-900776
|
DCIA82B
|
MK-1775
|
Adenocarcinoma (Cell Line: DLD1)
|
[4] |
|
MK-1775 + SCH-900776
|
DCEWOL1
|
MK-1775
|
Adenocarcinoma (Cell Line: HCT116)
|
[4] |
|
MK-1775 + SCH-900776
|
DCSTMED
|
MK-1775
|
Adenocarcinoma (Cell Line: HT29)
|
[4] |
|
MK-1775 + SCH-900776
|
DCA7ZQN
|
MK-1775
|
Amelanotic melanoma (Cell Line: A2058)
|
[4] |
|
MK-1775 + SCH-900776
|
DCHVP8T
|
MK-1775
|
Germ cell tumour (Cell Line: PA1)
|
[4] |
|
MK-1775 + SCH-900776
|
DC8HG4N
|
MK-1775
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[4] |
|
MK-1775 + SCH-900776
|
DCD281V
|
MK-1775
|
Malignant melanoma (Cell Line: A375)
|
[4] |
|
MK-1775 + SCH-900776
|
DC3ECQB
|
MK-1775
|
Malignant melanoma (Cell Line: HT144)
|
[4] |
|
MK-1775 + SCH-900776
|
DC4DUCX
|
MK-1775
|
Malignant melanoma (Cell Line: RPMI7951)
|
[4] |
|
MK-1775 + SCH-900776
|
DC34STB
|
MK-1775
|
Malignant melanoma (Cell Line: SKMEL30)
|
[4] |
|
MK-1775 + SCH-900776
|
DC7RI9T
|
MK-1775
|
Mesothelioma (Cell Line: MSTO)
|
[4] |
|
MK-1775 + SCH-900776
|
DCL0ELV
|
MK-1775
|
Ovarian endometrioid adenocarcinoma (Cell Line: A2780)
|
[4] |
|
MK-1775 + SCH-900776
|
DCXSBYW
|
MK-1775
|
Prostate carcinoma (Cell Line: VCAP)
|
[4] |
|
MK-1775 + SCH-900776
|
DCWS3AK
|
MK-1775
|
Breast carcinoma (Cell Line: ZR751)
|
[2] |
|
MK-1775 + SCH-900776
|
DC4F2BU
|
MK-1775
|
Breast carcinoma (Cell Line: OCUBM)
|
[2] |
|
MK-1775 + SCH-900776
|
DC06G64
|
MK-1775
|
Carcinoma (Cell Line: OV90)
|
[2] |
|
MK-1775 + SCH-900776
|
DC3AKDF
|
MK-1775
|
Colon carcinoma (Cell Line: RKO)
|
[2] |
|
MK-1775 + SCH-900776
|
DC89Z74
|
MK-1775
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[2] |
|
MK-2206 + SCH-900776
|
DCK98N5
|
MK-2206
|
Adenocarcinoma (Cell Line: CAOV3)
|
[4] |
|
MK-2206 + SCH-900776
|
DCAUUGZ
|
MK-2206
|
Adenocarcinoma (Cell Line: NCIH23)
|
[4] |
|
MK-2206 + SCH-900776
|
DCA065B
|
MK-2206
|
Adenocarcinoma (Cell Line: NCIH520)
|
[4] |
|
MK-2206 + SCH-900776
|
DCYAN7T
|
MK-2206
|
Adenocarcinoma (Cell Line: COLO320DM)
|
[4] |
|
MK-2206 + SCH-900776
|
DC9F0DX
|
MK-2206
|
Adenocarcinoma (Cell Line: HT29)
|
[4] |
|
MK-2206 + SCH-900776
|
DCFG7P7
|
MK-2206
|
Amelanotic melanoma (Cell Line: A2058)
|
[4] |
|
MK-2206 + SCH-900776
|
DCPF62G
|
MK-2206
|
Germ cell tumour (Cell Line: PA1)
|
[4] |
|
MK-2206 + SCH-900776
|
DCMCNEN
|
MK-2206
|
Malignant melanoma (Cell Line: A375)
|
[4] |
|
MK-2206 + SCH-900776
|
DCIH705
|
MK-2206
|
Malignant melanoma (Cell Line: HT144)
|
[4] |
|
MK-2206 + SCH-900776
|
DCAS7R5
|
MK-2206
|
Malignant melanoma (Cell Line: RPMI7951)
|
[4] |
|
MK-2206 + SCH-900776
|
DC1B2QJ
|
MK-2206
|
Malignant melanoma (Cell Line: UACC62)
|
[4] |
|
MK-2206 + SCH-900776
|
DCDZOHV
|
MK-2206
|
Mesothelioma (Cell Line: MSTO)
|
[4] |
|
MK-2206 + SCH-900776
|
DCY2P31
|
MK-2206
|
Non small cell carcinoma (Cell Line: SKMES1)
|
[4] |
|
MK-2206 + SCH-900776
|
DCG6WL7
|
MK-2206
|
Ovarian endometrioid adenocarcinoma (Cell Line: A2780)
|
[4] |
|
MK-2206 + SCH-900776
|
DCUY405
|
MK-2206
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[4] |
|
MK-2206 + SCH-900776
|
DCOVT6P
|
MK-2206
|
Prostate carcinoma (Cell Line: VCAP)
|
[4] |
|
MK-2206 + SCH-900776
|
DCP4CVK
|
MK-2206
|
Breast carcinoma (Cell Line: KPL1)
|
[2] |
|
MK-2206 + SCH-900776
|
DCAA1QS
|
MK-2206
|
Carcinoma (Cell Line: OV90)
|
[2] |
|
MK-2206 + SCH-900776
|
DC1P21L
|
MK-2206
|
Carcinoma (Cell Line: MDAMB436)
|
[2] |
|
MK-2206 + SCH-900776
|
DC3KEN4
|
MK-2206
|
Rectal adenocarcinoma (Cell Line: SW837)
|
[2] |
|
MK-4827 + SCH-900776
|
DC386N8
|
MK-4827
|
Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2)
|
[4] |
|
MK-4827 + SCH-900776
|
DCUNSD2
|
MK-4827
|
Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1)
|
[2] |
|
MK-4827 + SCH-900776
|
DC8BAL5
|
MK-4827
|
Breast carcinoma (Cell Line: KPL1)
|
[2] |
|
MK-4827 + SCH-900776
|
DC54IHN
|
MK-4827
|
Breast carcinoma (Cell Line: OCUBM)
|
[2] |
|
MK-4827 + SCH-900776
|
DCU2Y1O
|
MK-4827
|
Carcinoma (Cell Line: OV90)
|
[2] |
|
MK-4827 + SCH-900776
|
DCDZ94E
|
MK-4827
|
Carcinoma (Cell Line: MDAMB436)
|
[2] |
|
MK-4827 + SCH-900776
|
DCU5P5B
|
MK-4827
|
Colon carcinoma (Cell Line: RKO)
|
[2] |
|
MK-4827 + SCH-900776
|
DCQGSFQ
|
MK-4827
|
Rectal adenocarcinoma (Cell Line: SW837)
|
[2] |
|
MK-4827 + SCH-900776
|
DCJCNIO
|
MK-4827
|
Adenocarcinoma (Cell Line: CAOV3)
|
[3] |
|
MK-4827 + SCH-900776
|
DC2ECJ4
|
MK-4827
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[3] |
|
MK-4827 + SCH-900776
|
DCTHA6M
|
MK-4827
|
Adenocarcinoma (Cell Line: A427)
|
[3] |
|
MK-4827 + SCH-900776
|
DC4K3HZ
|
MK-4827
|
Adenocarcinoma (Cell Line: NCIH2122)
|
[3] |
|
MK-4827 + SCH-900776
|
DCIFKNW
|
MK-4827
|
Adenocarcinoma (Cell Line: NCIH23)
|
[3] |
|
MK-4827 + SCH-900776
|
DCLTPD7
|
MK-4827
|
Adenocarcinoma (Cell Line: COLO320DM)
|
[3] |
|
MK-4827 + SCH-900776
|
DC8OA8H
|
MK-4827
|
Adenocarcinoma (Cell Line: DLD1)
|
[3] |
|
MK-4827 + SCH-900776
|
DCCTRVY
|
MK-4827
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
MK-4827 + SCH-900776
|
DCYKMNN
|
MK-4827
|
Amelanotic melanoma (Cell Line: A2058)
|
[3] |
|
MK-4827 + SCH-900776
|
DC1TZ3T
|
MK-4827
|
Germ cell tumour (Cell Line: PA1)
|
[3] |
|
MK-4827 + SCH-900776
|
DCB1LP2
|
MK-4827
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
MK-4827 + SCH-900776
|
DC1DY7H
|
MK-4827
|
Malignant melanoma (Cell Line: A375)
|
[3] |
|
MK-4827 + SCH-900776
|
DC6MF7R
|
MK-4827
|
Malignant melanoma (Cell Line: HT144)
|
[3] |
|
MK-4827 + SCH-900776
|
DCL5VYC
|
MK-4827
|
Malignant melanoma (Cell Line: RPMI7951)
|
[3] |
|
MK-4827 + SCH-900776
|
DCC65TQ
|
MK-4827
|
Malignant melanoma (Cell Line: SKMEL30)
|
[3] |
|
MK-4827 + SCH-900776
|
DCPFW2S
|
MK-4827
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
MK-4827 + SCH-900776
|
DC5NJSB
|
MK-4827
|
Mesothelioma (Cell Line: MSTO)
|
[3] |
|
MK-4827 + SCH-900776
|
DCFLMGE
|
MK-4827
|
Non small cell carcinoma (Cell Line: SKMES1)
|
[3] |
|
MK-4827 + SCH-900776
|
DC23HDQ
|
MK-4827
|
Ovarian endometrioid adenocarcinoma (Cell Line: A2780)
|
[3] |
|
MK-4827 + SCH-900776
|
DCPYSTM
|
MK-4827
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[3] |
|
MK-5108 + SCH-900776
|
DC2MX6C
|
MK-5108
|
Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1)
|
[2] |
|
MK-5108 + SCH-900776
|
DCWYU7K
|
MK-5108
|
Carcinoma (Cell Line: EFM192B)
|
[2] |
|
MK-5108 + SCH-900776
|
DCUFS33
|
MK-5108
|
Adenocarcinoma (Cell Line: CAOV3)
|
[3] |
|
MK-5108 + SCH-900776
|
DCBWXWD
|
MK-5108
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[3] |
|
MK-5108 + SCH-900776
|
DCGAT18
|
MK-5108
|
Adenocarcinoma (Cell Line: A427)
|
[3] |
|
MK-5108 + SCH-900776
|
DC8TA85
|
MK-5108
|
Adenocarcinoma (Cell Line: NCIH23)
|
[3] |
|
MK-5108 + SCH-900776
|
DC7Q4W3
|
MK-5108
|
Adenocarcinoma (Cell Line: HCT116)
|
[3] |
|
MK-5108 + SCH-900776
|
DCUJWM8
|
MK-5108
|
Germ cell tumour (Cell Line: PA1)
|
[3] |
|
MK-5108 + SCH-900776
|
DCDW1MY
|
MK-5108
|
Malignant melanoma (Cell Line: A375)
|
[3] |
|
MK-5108 + SCH-900776
|
DCSRLNB
|
MK-5108
|
Malignant melanoma (Cell Line: RPMI7951)
|
[3] |
|
MK-5108 + SCH-900776
|
DCPZPWL
|
MK-5108
|
Malignant melanoma (Cell Line: SKMEL30)
|
[3] |
|
MK-5108 + SCH-900776
|
DCHU1F9
|
MK-5108
|
Ovarian endometrioid adenocarcinoma (Cell Line: A2780)
|
[3] |
|
PD-0325901 + SCH-900776
|
DCTPGKQ
|
PD-0325901
|
Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2)
|
[4] |
|
PD-0325901 + SCH-900776
|
DCJD918
|
PD-0325901
|
Breast and ovarian cancer syndrome (Cell Line: UWB1289)
|
[2] |
|
PD-0325901 + SCH-900776
|
DCDJ47S
|
PD-0325901
|
Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1)
|
[2] |
|
PD-0325901 + SCH-900776
|
DC2KRHM
|
PD-0325901
|
Breast carcinoma (Cell Line: ZR751)
|
[2] |
|
PD-0325901 + SCH-900776
|
DCIJO1L
|
PD-0325901
|
Breast carcinoma (Cell Line: KPL1)
|
[2] |
|
PD-0325901 + SCH-900776
|
DCRV0EF
|
PD-0325901
|
Breast carcinoma (Cell Line: OCUBM)
|
[2] |
|
PD-0325901 + SCH-900776
|
DCU8VN3
|
PD-0325901
|
Carcinoma (Cell Line: OV90)
|
[2] |
|
PD-0325901 + SCH-900776
|
DC0DYS3
|
PD-0325901
|
Carcinoma (Cell Line: EFM192B)
|
[2] |
|
PD-0325901 + SCH-900776
|
DCJBXEG
|
PD-0325901
|
Carcinoma (Cell Line: MDAMB436)
|
[2] |
|
PD-0325901 + SCH-900776
|
DCKUOMF
|
PD-0325901
|
Colon adenocarcinoma (Cell Line: LOVO)
|
[2] |
|
PD-0325901 + SCH-900776
|
DC8ER24
|
PD-0325901
|
Colon carcinoma (Cell Line: RKO)
|
[2] |
|
PD-0325901 + SCH-900776
|
DCCTA4P
|
PD-0325901
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[2] |
|
PD-0325901 + SCH-900776
|
DCPN5FX
|
PD-0325901
|
Rectal adenocarcinoma (Cell Line: SW837)
|
[2] |
|
PD-0325901 + SCH-900776
|
DCYANX5
|
PD-0325901
|
Adenocarcinoma (Cell Line: CAOV3)
|
[3] |
|
PD-0325901 + SCH-900776
|
DC5ESLA
|
PD-0325901
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[3] |
|
PD-0325901 + SCH-900776
|
DCJBZHM
|
PD-0325901
|
Adenocarcinoma (Cell Line: A427)
|
[3] |
|
PD-0325901 + SCH-900776
|
DCTJ42V
|
PD-0325901
|
Adenocarcinoma (Cell Line: NCIH1650)
|
[3] |
|
PD-0325901 + SCH-900776
|
DCLTK66
|
PD-0325901
|
Adenocarcinoma (Cell Line: NCIH2122)
|
[3] |
|
PD-0325901 + SCH-900776
|
DCY6D4G
|
PD-0325901
|
Adenocarcinoma (Cell Line: NCIH520)
|
[3] |
|
PD-0325901 + SCH-900776
|
DCYS15M
|
PD-0325901
|
Adenocarcinoma (Cell Line: NCIH23)
|
[3] |
|
PD-0325901 + SCH-900776
|
DCZX04W
|
PD-0325901
|
Adenocarcinoma (Cell Line: COLO320DM)
|
[3] |
|
PD-0325901 + SCH-900776
|
DCT9MXN
|
PD-0325901
|
Adenocarcinoma (Cell Line: DLD1)
|
[3] |
|
PD-0325901 + SCH-900776
|
DCDUUL8
|
PD-0325901
|
Adenocarcinoma (Cell Line: HCT116)
|
[3] |
|
PD-0325901 + SCH-900776
|
DC7HB22
|
PD-0325901
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
PD-0325901 + SCH-900776
|
DC22HS5
|
PD-0325901
|
Amelanotic melanoma (Cell Line: A2058)
|
[3] |
|
PD-0325901 + SCH-900776
|
DCGR703
|
PD-0325901
|
Germ cell tumour (Cell Line: PA1)
|
[3] |
|
PD-0325901 + SCH-900776
|
DCRM7NJ
|
PD-0325901
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
PD-0325901 + SCH-900776
|
DCUA35G
|
PD-0325901
|
Malignant melanoma (Cell Line: A375)
|
[3] |
|
PD-0325901 + SCH-900776
|
DCUO06E
|
PD-0325901
|
Malignant melanoma (Cell Line: HT144)
|
[3] |
|
PD-0325901 + SCH-900776
|
DCGU16B
|
PD-0325901
|
Malignant melanoma (Cell Line: RPMI7951)
|
[3] |
|
PD-0325901 + SCH-900776
|
DCYXXVZ
|
PD-0325901
|
Malignant melanoma (Cell Line: SKMEL30)
|
[3] |
|
PD-0325901 + SCH-900776
|
DCCQ6JF
|
PD-0325901
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
PD-0325901 + SCH-900776
|
DC2S567
|
PD-0325901
|
Mesothelioma (Cell Line: MSTO)
|
[3] |
|
PD-0325901 + SCH-900776
|
DCRVE4Y
|
PD-0325901
|
Non small cell carcinoma (Cell Line: SKMES1)
|
[3] |
|
PD-0325901 + SCH-900776
|
DC9BXKS
|
PD-0325901
|
Ovarian endometrioid adenocarcinoma (Cell Line: A2780)
|
[3] |
|
PD-0325901 + SCH-900776
|
DCYRM3Z
|
PD-0325901
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[3] |
|
PD-0325901 + SCH-900776
|
DCGPVZF
|
PD-0325901
|
Prostate carcinoma (Cell Line: VCAP)
|
[3] |
|
PD-0325901 + SCH-900776
|
DC86OK9
|
PD-0325901
|
Prostate carcinoma (Cell Line: LNCAP)
|
[3] |
|
PMID28460551-Compound-2 + SCH-900776
|
DCY4RGE
|
PMID28460551-Compound-2
|
Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2)
|
[4] |
|
PMID28460551-Compound-2 + SCH-900776
|
DC4UN7X
|
PMID28460551-Compound-2
|
Breast and ovarian cancer syndrome (Cell Line: UWB1289)
|
[2] |
|
PMID28460551-Compound-2 + SCH-900776
|
DCM4HHD
|
PMID28460551-Compound-2
|
Breast carcinoma (Cell Line: OCUBM)
|
[2] |
|
PMID28460551-Compound-2 + SCH-900776
|
DCRMHVY
|
PMID28460551-Compound-2
|
Carcinoma (Cell Line: OV90)
|
[2] |
|
PMID28460551-Compound-2 + SCH-900776
|
DCWZJ86
|
PMID28460551-Compound-2
|
Carcinoma (Cell Line: MDAMB436)
|
[2] |
|
PMID28460551-Compound-2 + SCH-900776
|
DC0J1O2
|
PMID28460551-Compound-2
|
Colon adenocarcinoma (Cell Line: LOVO)
|
[2] |
|
PMID28460551-Compound-2 + SCH-900776
|
DC7MIHC
|
PMID28460551-Compound-2
|
Colon carcinoma (Cell Line: RKO)
|
[2] |
|
PMID28460551-Compound-2 + SCH-900776
|
DCQVA1G
|
PMID28460551-Compound-2
|
Rectal adenocarcinoma (Cell Line: SW837)
|
[2] |
|
PMID28460551-Compound-2 + SCH-900776
|
DCQN0PH
|
PMID28460551-Compound-2
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[3] |
|
PMID28460551-Compound-2 + SCH-900776
|
DCNKJ52
|
PMID28460551-Compound-2
|
Adenocarcinoma (Cell Line: CAOV3)
|
[3] |
|
PMID28460551-Compound-2 + SCH-900776
|
DCE0GNZ
|
PMID28460551-Compound-2
|
Adenocarcinoma (Cell Line: NCIH2122)
|
[3] |
|
PMID28460551-Compound-2 + SCH-900776
|
DCPA4RV
|
PMID28460551-Compound-2
|
Adenocarcinoma (Cell Line: NCIH23)
|
[3] |
|
PMID28460551-Compound-2 + SCH-900776
|
DCS0XKO
|
PMID28460551-Compound-2
|
Adenocarcinoma (Cell Line: NCIH520)
|
[3] |
|
PMID28460551-Compound-2 + SCH-900776
|
DCIZDRR
|
PMID28460551-Compound-2
|
Adenocarcinoma (Cell Line: COLO320DM)
|
[3] |
|
PMID28460551-Compound-2 + SCH-900776
|
DCBYLID
|
PMID28460551-Compound-2
|
Adenocarcinoma (Cell Line: DLD1)
|
[3] |
|
PMID28460551-Compound-2 + SCH-900776
|
DCJZSO1
|
PMID28460551-Compound-2
|
Adenocarcinoma (Cell Line: HCT116)
|
[3] |
|
PMID28460551-Compound-2 + SCH-900776
|
DCCT50G
|
PMID28460551-Compound-2
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
PMID28460551-Compound-2 + SCH-900776
|
DCYJD69
|
PMID28460551-Compound-2
|
Amelanotic melanoma (Cell Line: A2058)
|
[3] |
|
PMID28460551-Compound-2 + SCH-900776
|
DCMCMVY
|
PMID28460551-Compound-2
|
Germ cell tumour (Cell Line: PA1)
|
[3] |
|
PMID28460551-Compound-2 + SCH-900776
|
DCV2XN1
|
PMID28460551-Compound-2
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
PMID28460551-Compound-2 + SCH-900776
|
DC1W2J7
|
PMID28460551-Compound-2
|
Malignant melanoma (Cell Line: A375)
|
[3] |
|
PMID28460551-Compound-2 + SCH-900776
|
DCISX8I
|
PMID28460551-Compound-2
|
Malignant melanoma (Cell Line: HT144)
|
[3] |
|
PMID28460551-Compound-2 + SCH-900776
|
DC0SUH2
|
PMID28460551-Compound-2
|
Malignant melanoma (Cell Line: RPMI7951)
|
[3] |
|
PMID28460551-Compound-2 + SCH-900776
|
DCS234W
|
PMID28460551-Compound-2
|
Malignant melanoma (Cell Line: SKMEL30)
|
[3] |
|
PMID28460551-Compound-2 + SCH-900776
|
DCCQFJ0
|
PMID28460551-Compound-2
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
PMID28460551-Compound-2 + SCH-900776
|
DC176V4
|
PMID28460551-Compound-2
|
Mesothelioma (Cell Line: MSTO)
|
[3] |
|
PMID28460551-Compound-2 + SCH-900776
|
DCFD8U8
|
PMID28460551-Compound-2
|
Non small cell carcinoma (Cell Line: SKMES1)
|
[3] |
|
PMID28460551-Compound-2 + SCH-900776
|
DCGRXZ7
|
PMID28460551-Compound-2
|
Ovarian endometrioid adenocarcinoma (Cell Line: A2780)
|
[3] |
|
PMID28460551-Compound-2 + SCH-900776
|
DCO81SW
|
PMID28460551-Compound-2
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[3] |
|
PMID28460551-Compound-2 + SCH-900776
|
DC852SR
|
PMID28460551-Compound-2
|
Prostate carcinoma (Cell Line: LNCAP)
|
[3] |
|
PMID28460551-Compound-2 + SCH-900776
|
DC2VE9B
|
PMID28460551-Compound-2
|
Prostate carcinoma (Cell Line: VCAP)
|
[3] |
|
Ridaforolimus + SCH-900776
|
DCWZ7WW
|
Ridaforolimus
|
Colon carcinoma (Cell Line: RKO)
|
[2] |
|
Ridaforolimus + SCH-900776
|
DCESKXL
|
Ridaforolimus
|
Rectal adenocarcinoma (Cell Line: SW837)
|
[2] |
|
Ridaforolimus + SCH-900776
|
DCK3IF8
|
Ridaforolimus
|
Adenocarcinoma (Cell Line: COLO320DM)
|
[3] |
|
Ridaforolimus + SCH-900776
|
DCPML0E
|
Ridaforolimus
|
Adenocarcinoma (Cell Line: HCT116)
|
[3] |
|
Ridaforolimus + SCH-900776
|
DC6TMI8
|
Ridaforolimus
|
Germ cell tumour (Cell Line: PA1)
|
[3] |
|
Ridaforolimus + SCH-900776
|
DCRR8RL
|
Ridaforolimus
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
Ridaforolimus + SCH-900776
|
DCUABO8
|
Ridaforolimus
|
Malignant melanoma (Cell Line: A375)
|
[3] |
|
Ridaforolimus + SCH-900776
|
DCFM6EN
|
Ridaforolimus
|
Malignant melanoma (Cell Line: RPMI7951)
|
[3] |
|
Ridaforolimus + SCH-900776
|
DCZZMXP
|
Ridaforolimus
|
Ovarian endometrioid adenocarcinoma (Cell Line: A2780)
|
[3] |
|
Ridaforolimus + SCH-900776
|
DCZOY5B
|
Ridaforolimus
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[3] |
|
RTB101 + SCH-900776
|
DCLNLE2
|
RTB101
|
Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2)
|
[4] |
|
RTB101 + SCH-900776
|
DCJTRP0
|
RTB101
|
Breast and ovarian cancer syndrome (Cell Line: UWB1289)
|
[2] |
|
RTB101 + SCH-900776
|
DCMMMHJ
|
RTB101
|
Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1)
|
[2] |
|
RTB101 + SCH-900776
|
DCXS7DH
|
RTB101
|
Carcinoma (Cell Line: OV90)
|
[2] |
|
RTB101 + SCH-900776
|
DCWJIQJ
|
RTB101
|
Carcinoma (Cell Line: MDAMB436)
|
[2] |
|
RTB101 + SCH-900776
|
DC0AU7S
|
RTB101
|
Colon carcinoma (Cell Line: RKO)
|
[2] |
|
RTB101 + SCH-900776
|
DC2AJYS
|
RTB101
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[3] |
|
RTB101 + SCH-900776
|
DCAVLNZ
|
RTB101
|
Adenocarcinoma (Cell Line: A427)
|
[3] |
|
RTB101 + SCH-900776
|
DCYMZHV
|
RTB101
|
Adenocarcinoma (Cell Line: NCIH2122)
|
[3] |
|
RTB101 + SCH-900776
|
DCN0Q5D
|
RTB101
|
Adenocarcinoma (Cell Line: NCIH23)
|
[3] |
|
RTB101 + SCH-900776
|
DCKA5NH
|
RTB101
|
Adenocarcinoma (Cell Line: NCIH520)
|
[3] |
|
RTB101 + SCH-900776
|
DC2QPIS
|
RTB101
|
Adenocarcinoma (Cell Line: COLO320DM)
|
[3] |
|
RTB101 + SCH-900776
|
DCFO2BC
|
RTB101
|
Adenocarcinoma (Cell Line: HCT116)
|
[3] |
|
RTB101 + SCH-900776
|
DCDEWZD
|
RTB101
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
RTB101 + SCH-900776
|
DCTFSEU
|
RTB101
|
Amelanotic melanoma (Cell Line: A2058)
|
[3] |
|
RTB101 + SCH-900776
|
DCTMSTN
|
RTB101
|
Germ cell tumour (Cell Line: PA1)
|
[3] |
|
RTB101 + SCH-900776
|
DCVONCU
|
RTB101
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
RTB101 + SCH-900776
|
DCDOI0G
|
RTB101
|
Malignant melanoma (Cell Line: A375)
|
[3] |
|
RTB101 + SCH-900776
|
DCY2RQO
|
RTB101
|
Malignant melanoma (Cell Line: RPMI7951)
|
[3] |
|
RTB101 + SCH-900776
|
DCOS18K
|
RTB101
|
Malignant melanoma (Cell Line: SKMEL30)
|
[3] |
|
RTB101 + SCH-900776
|
DC4331X
|
RTB101
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
RTB101 + SCH-900776
|
DCYXLID
|
RTB101
|
Mesothelioma (Cell Line: MSTO)
|
[3] |
|
RTB101 + SCH-900776
|
DCJJ5G0
|
RTB101
|
Non small cell carcinoma (Cell Line: SKMES1)
|
[3] |
|
RTB101 + SCH-900776
|
DCMI9TQ
|
RTB101
|
Ovarian endometrioid adenocarcinoma (Cell Line: A2780)
|
[3] |
|
RTB101 + SCH-900776
|
DCO053M
|
RTB101
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[3] |
|
RTB101 + SCH-900776
|
DC8QJPQ
|
RTB101
|
Prostate carcinoma (Cell Line: VCAP)
|
[3] |
|
SCH 727965 + SCH-900776
|
DCTFAHC
|
SCH 727965
|
Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2)
|
[4] |
|
SCH 727965 + SCH-900776
|
DC9Z8IP
|
SCH 727965
|
Carcinoma (Cell Line: OV90)
|
[2] |
|
SCH 727965 + SCH-900776
|
DCYGQRW
|
SCH 727965
|
Carcinoma (Cell Line: MDAMB436)
|
[2] |
|
SCH 727965 + SCH-900776
|
DC7U843
|
SCH 727965
|
Colon carcinoma (Cell Line: RKO)
|
[2] |
|
SCH 727965 + SCH-900776
|
DCLL6ON
|
SCH 727965
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[2] |
|
SCH 727965 + SCH-900776
|
DCA6RV1
|
SCH 727965
|
Adenocarcinoma (Cell Line: CAOV3)
|
[3] |
|
SCH 727965 + SCH-900776
|
DCO77CY
|
SCH 727965
|
Adenocarcinoma (Cell Line: A427)
|
[3] |
|
SCH 727965 + SCH-900776
|
DC4V54L
|
SCH 727965
|
Adenocarcinoma (Cell Line: NCIH520)
|
[3] |
|
SCH 727965 + SCH-900776
|
DC7K0MG
|
SCH 727965
|
Adenocarcinoma (Cell Line: COLO320DM)
|
[3] |
|
SCH 727965 + SCH-900776
|
DC29FJP
|
SCH 727965
|
Adenocarcinoma (Cell Line: DLD1)
|
[3] |
|
SCH 727965 + SCH-900776
|
DCFSSX6
|
SCH 727965
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
SCH 727965 + SCH-900776
|
DC4XTCM
|
SCH 727965
|
Adenocarcinoma (Cell Line: HCT116)
|
[3] |
|
SCH 727965 + SCH-900776
|
DCJL27L
|
SCH 727965
|
Amelanotic melanoma (Cell Line: A2058)
|
[3] |
|
SCH 727965 + SCH-900776
|
DCVDCC9
|
SCH 727965
|
Germ cell tumour (Cell Line: PA1)
|
[3] |
|
SCH 727965 + SCH-900776
|
DCMJTED
|
SCH 727965
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
SCH 727965 + SCH-900776
|
DCV9UV4
|
SCH 727965
|
Malignant melanoma (Cell Line: A375)
|
[3] |
|
SCH 727965 + SCH-900776
|
DCPBTAA
|
SCH 727965
|
Malignant melanoma (Cell Line: HT144)
|
[3] |
|
SCH 727965 + SCH-900776
|
DCDGA0L
|
SCH 727965
|
Malignant melanoma (Cell Line: RPMI7951)
|
[3] |
|
SCH 727965 + SCH-900776
|
DC7HJMU
|
SCH 727965
|
Malignant melanoma (Cell Line: SKMEL30)
|
[3] |
|
SCH 727965 + SCH-900776
|
DCOXZUA
|
SCH 727965
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
SCH 727965 + SCH-900776
|
DCMC99S
|
SCH 727965
|
Mesothelioma (Cell Line: MSTO)
|
[3] |
|
SCH 727965 + SCH-900776
|
DC5VA04
|
SCH 727965
|
Ovarian endometrioid adenocarcinoma (Cell Line: A2780)
|
[3] |
|
SCH 727965 + SCH-900776
|
DCMTY2S
|
SCH 727965
|
Prostate carcinoma (Cell Line: VCAP)
|
[3] |
|
SCH-900776 + Buparlisib
|
DCBSSGQ
|
Buparlisib
|
Ewing sarcoma (Cell Line: TC-71)
|
[4] |
|
SCH-900776 + MK-1775
|
DCDWQ24
|
MK-1775
|
Ewing sarcoma (Cell Line: TC-71)
|
[4] |
|
SCH-900776 + Artemether
|
DC2BQFO
|
Artemether
|
Ewing sarcoma (Cell Line: TC-71)
|
[4] |
|
SCH-900776 + Panobinostat
|
DCI9VGZ
|
Panobinostat
|
Diffuse intrinsic pontine glioma (Cell Line: DIPG25)
|
[4] |
|
SCH-900776 + Panobinostat
|
DC7EPYS
|
Panobinostat
|
Ewing sarcoma (Cell Line: TC-71)
|
[4] |
|
SCH-900776 + Docetaxel
|
DCOC4E4
|
Docetaxel
|
Ewing sarcoma (Cell Line: TC-71)
|
[4] |
|
SCH-900776 + OSI-906
|
DCDRFBW
|
OSI-906
|
Ewing sarcoma (Cell Line: TC-71)
|
[4] |
|
SCH-900776 + Idarubicin
|
DCHVXC5
|
Idarubicin
|
Glioblastoma? (Cell Line: T98G)
|
[4] |
|
SCH-900776 + Ruxolitinib
|
DCD5WAE
|
Ruxolitinib
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[3] |
|
SNX-2112 + SCH-900776
|
DCSGE3K
|
SNX-2112
|
Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1)
|
[2] |
|
SNX-2112 + SCH-900776
|
DC70BBV
|
SNX-2112
|
Breast carcinoma (Cell Line: ZR751)
|
[2] |
|
SNX-2112 + SCH-900776
|
DCS8LTK
|
SNX-2112
|
Breast carcinoma (Cell Line: OCUBM)
|
[2] |
|
SNX-2112 + SCH-900776
|
DCM5DGZ
|
SNX-2112
|
Colon adenocarcinoma (Cell Line: LOVO)
|
[2] |
|
SNX-2112 + SCH-900776
|
DCOS7Z3
|
SNX-2112
|
Colon carcinoma (Cell Line: RKO)
|
[2] |
|
SNX-2112 + SCH-900776
|
DC54AX7
|
SNX-2112
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[2] |
|
SNX-2112 + SCH-900776
|
DCIQW8V
|
SNX-2112
|
Adenocarcinoma (Cell Line: CAOV3)
|
[3] |
|
SNX-2112 + SCH-900776
|
DCVI0RN
|
SNX-2112
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[3] |
|
SNX-2112 + SCH-900776
|
DCZVWLF
|
SNX-2112
|
Adenocarcinoma (Cell Line: A427)
|
[3] |
|
SNX-2112 + SCH-900776
|
DCRA17M
|
SNX-2112
|
Adenocarcinoma (Cell Line: NCIH1650)
|
[3] |
|
SNX-2112 + SCH-900776
|
DC6L3R1
|
SNX-2112
|
Adenocarcinoma (Cell Line: NCIH2122)
|
[3] |
|
SNX-2112 + SCH-900776
|
DCH3CLJ
|
SNX-2112
|
Adenocarcinoma (Cell Line: NCIH520)
|
[3] |
|
SNX-2112 + SCH-900776
|
DCCF31U
|
SNX-2112
|
Adenocarcinoma (Cell Line: COLO320DM)
|
[3] |
|
SNX-2112 + SCH-900776
|
DCBUEBJ
|
SNX-2112
|
Adenocarcinoma (Cell Line: DLD1)
|
[3] |
|
SNX-2112 + SCH-900776
|
DCYQVWB
|
SNX-2112
|
Adenocarcinoma (Cell Line: HCT116)
|
[3] |
|
SNX-2112 + SCH-900776
|
DCZ025U
|
SNX-2112
|
Amelanotic melanoma (Cell Line: A2058)
|
[3] |
|
SNX-2112 + SCH-900776
|
DCTRQ8I
|
SNX-2112
|
Germ cell tumour (Cell Line: PA1)
|
[3] |
|
SNX-2112 + SCH-900776
|
DCINTEM
|
SNX-2112
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
SNX-2112 + SCH-900776
|
DCE83OL
|
SNX-2112
|
Malignant melanoma (Cell Line: A375)
|
[3] |
|
SNX-2112 + SCH-900776
|
DCZN7ND
|
SNX-2112
|
Malignant melanoma (Cell Line: RPMI7951)
|
[3] |
|
SNX-2112 + SCH-900776
|
DC2Q7Y0
|
SNX-2112
|
Malignant melanoma (Cell Line: SKMEL30)
|
[3] |
|
SNX-2112 + SCH-900776
|
DCAJULH
|
SNX-2112
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
SNX-2112 + SCH-900776
|
DCUV7VP
|
SNX-2112
|
Non small cell carcinoma (Cell Line: SKMES1)
|
[3] |
|
SNX-2112 + SCH-900776
|
DC2ZD5K
|
SNX-2112
|
Ovarian endometrioid adenocarcinoma (Cell Line: A2780)
|
[3] |
|
SNX-2112 + SCH-900776
|
DC0EUZC
|
SNX-2112
|
Prostate carcinoma (Cell Line: VCAP)
|
[3] |
|
Sorafenib + SCH-900776
|
DC81EMZ
|
Sorafenib
|
Adenocarcinoma (Cell Line: CAOV3)
|
[4] |
|
Sorafenib + SCH-900776
|
DCBMWF4
|
Sorafenib
|
Adenocarcinoma (Cell Line: A427)
|
[4] |
|
Sorafenib + SCH-900776
|
DCZNKAK
|
Sorafenib
|
Adenocarcinoma (Cell Line: NCIH1650)
|
[4] |
|
Sorafenib + SCH-900776
|
DCLK3FG
|
Sorafenib
|
Adenocarcinoma (Cell Line: NCIH520)
|
[4] |
|
Sorafenib + SCH-900776
|
DCAW05E
|
Sorafenib
|
Adenocarcinoma (Cell Line: COLO320DM)
|
[4] |
|
Sorafenib + SCH-900776
|
DCKWV87
|
Sorafenib
|
Adenocarcinoma (Cell Line: DLD1)
|
[4] |
|
Sorafenib + SCH-900776
|
DCRFD5W
|
Sorafenib
|
Adenocarcinoma (Cell Line: HCT116)
|
[4] |
|
Sorafenib + SCH-900776
|
DC38072
|
Sorafenib
|
Adenocarcinoma (Cell Line: HT29)
|
[4] |
|
Sorafenib + SCH-900776
|
DCKIVXQ
|
Sorafenib
|
Adenocarcinoma (Cell Line: SW-620)
|
[4] |
|
Sorafenib + SCH-900776
|
DC4S540
|
Sorafenib
|
Amelanotic melanoma (Cell Line: A2058)
|
[4] |
|
Sorafenib + SCH-900776
|
DCQ8Q6M
|
Sorafenib
|
Germ cell tumour (Cell Line: PA1)
|
[4] |
|
Sorafenib + SCH-900776
|
DCHJ5YR
|
Sorafenib
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[4] |
|
Sorafenib + SCH-900776
|
DC9W6P1
|
Sorafenib
|
Malignant melanoma (Cell Line: A375)
|
[4] |
|
Sorafenib + SCH-900776
|
DCHNOJL
|
Sorafenib
|
Malignant melanoma (Cell Line: HT144)
|
[4] |
|
Sorafenib + SCH-900776
|
DCK7WSQ
|
Sorafenib
|
Malignant melanoma (Cell Line: UACC62)
|
[4] |
|
Sorafenib + SCH-900776
|
DC0RPBP
|
Sorafenib
|
Mesothelioma (Cell Line: MSTO)
|
[4] |
|
Sorafenib + SCH-900776
|
DCVRF8M
|
Sorafenib
|
Ovarian endometrioid adenocarcinoma (Cell Line: A2780)
|
[4] |
|
Sorafenib + SCH-900776
|
DCIAKHZ
|
Sorafenib
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[4] |
|
Sorafenib + SCH-900776
|
DCEX2RA
|
Sorafenib
|
Prostate carcinoma (Cell Line: LNCAP)
|
[4] |
|
Sorafenib + SCH-900776
|
DCO6N32
|
Sorafenib
|
Prostate carcinoma (Cell Line: VCAP)
|
[4] |
|
Sorafenib + SCH-900776
|
DCZ568W
|
Sorafenib
|
Breast carcinoma (Cell Line: ZR751)
|
[2] |
|
Sorafenib + SCH-900776
|
DCI85JI
|
Sorafenib
|
Breast carcinoma (Cell Line: OCUBM)
|
[2] |
|
Sorafenib + SCH-900776
|
DCMAZTI
|
Sorafenib
|
Carcinoma (Cell Line: OV90)
|
[2] |
|
Sorafenib + SCH-900776
|
DC5PK6D
|
Sorafenib
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[2] |
|
Taxol + SCH-900776
|
DCEW2SX
|
Taxol
|
Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2)
|
[4] |
|
Taxol + SCH-900776
|
DCAHCR1
|
Taxol
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[3] |
|
Taxol + SCH-900776
|
DCQ1CLF
|
Taxol
|
Adenocarcinoma (Cell Line: COLO320DM)
|
[3] |
|
Taxol + SCH-900776
|
DCKA3X6
|
Taxol
|
Malignant melanoma (Cell Line: A375)
|
[3] |
|
Taxol + SCH-900776
|
DC5I0N9
|
Taxol
|
Malignant melanoma (Cell Line: RPMI7951)
|
[3] |
|
Taxol + SCH-900776
|
DCBS0X9
|
Taxol
|
Mesothelioma (Cell Line: MSTO)
|
[3] |
|
Taxol + SCH-900776
|
DCNQDIF
|
Taxol
|
Non small cell carcinoma (Cell Line: SKMES1)
|
[3] |
|
Taxol + SCH-900776
|
DCQD7SS
|
Taxol
|
Ovarian endometrioid adenocarcinoma (Cell Line: A2780)
|
[3] |
|
Taxol + SCH-900776
|
DC57ZNT
|
Taxol
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[3] |
|
Topotecan + SCH-900776
|
DCWABDW
|
Topotecan
|
Breast carcinoma (Cell Line: OCUBM)
|
[2] |
|
Topotecan + SCH-900776
|
DC4E407
|
Topotecan
|
Carcinoma (Cell Line: MDAMB436)
|
[2] |
|
Topotecan + SCH-900776
|
DC4AXUJ
|
Topotecan
|
Carcinoma (Cell Line: EFM192B)
|
[2] |
|
Topotecan + SCH-900776
|
DCXVDME
|
Topotecan
|
Colon adenocarcinoma (Cell Line: LOVO)
|
[2] |
|
Topotecan + SCH-900776
|
DC0K9WT
|
Topotecan
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[2] |
|
Topotecan + SCH-900776
|
DCFP594
|
Topotecan
|
Adenocarcinoma (Cell Line: CAOV3)
|
[3] |
|
Topotecan + SCH-900776
|
DCC7FHS
|
Topotecan
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[3] |
|
Topotecan + SCH-900776
|
DCAMOSF
|
Topotecan
|
Adenocarcinoma (Cell Line: A427)
|
[3] |
|
Topotecan + SCH-900776
|
DCI3SHT
|
Topotecan
|
Adenocarcinoma (Cell Line: NCIH2122)
|
[3] |
|
Topotecan + SCH-900776
|
DCLSTM8
|
Topotecan
|
Adenocarcinoma (Cell Line: NCIH520)
|
[3] |
|
Topotecan + SCH-900776
|
DCBW31M
|
Topotecan
|
Adenocarcinoma (Cell Line: NCIH1650)
|
[3] |
|
Topotecan + SCH-900776
|
DCLR5OW
|
Topotecan
|
Adenocarcinoma (Cell Line: COLO320DM)
|
[3] |
|
Topotecan + SCH-900776
|
DC7M74Y
|
Topotecan
|
Adenocarcinoma (Cell Line: DLD1)
|
[3] |
|
Topotecan + SCH-900776
|
DC922SZ
|
Topotecan
|
Adenocarcinoma (Cell Line: HCT116)
|
[3] |
|
Topotecan + SCH-900776
|
DCETFRA
|
Topotecan
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
Topotecan + SCH-900776
|
DCTUVI2
|
Topotecan
|
Adenocarcinoma (Cell Line: SW-620)
|
[3] |
|
Topotecan + SCH-900776
|
DCVZGGG
|
Topotecan
|
Amelanotic melanoma (Cell Line: A2058)
|
[3] |
|
Topotecan + SCH-900776
|
DC6BGOC
|
Topotecan
|
Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2)
|
[3] |
|
Topotecan + SCH-900776
|
DCS4JPW
|
Topotecan
|
Germ cell tumour (Cell Line: PA1)
|
[3] |
|
Topotecan + SCH-900776
|
DCRYU0H
|
Topotecan
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
Topotecan + SCH-900776
|
DC1UO09
|
Topotecan
|
Malignant melanoma (Cell Line: A375)
|
[3] |
|
Topotecan + SCH-900776
|
DCM3L9F
|
Topotecan
|
Malignant melanoma (Cell Line: RPMI7951)
|
[3] |
|
Topotecan + SCH-900776
|
DCV0ROY
|
Topotecan
|
Non small cell carcinoma (Cell Line: SKMES1)
|
[3] |
|
Topotecan + SCH-900776
|
DCZYAM4
|
Topotecan
|
Ovarian endometrioid adenocarcinoma (Cell Line: A2780)
|
[3] |
|
Topotecan + SCH-900776
|
DCZM1E2
|
Topotecan
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[3] |
|
Vinblastine + SCH-900776
|
DCXK3ZS
|
Vinblastine
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[4] |
|
Vinblastine + SCH-900776
|
DCZ1N9R
|
Vinblastine
|
Adenocarcinoma (Cell Line: COLO320DM)
|
[4] |
|
Vinblastine + SCH-900776
|
DC5FDW4
|
Vinblastine
|
Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2)
|
[4] |
|
Vinblastine + SCH-900776
|
DCKE7MP
|
Vinblastine
|
Malignant melanoma (Cell Line: RPMI7951)
|
[4] |
|
Vinblastine + SCH-900776
|
DC1DYLJ
|
Vinblastine
|
Malignant melanoma (Cell Line: UACC62)
|
[4] |
|
Vinblastine + SCH-900776
|
DC4EV00
|
Vinblastine
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[4] |
|
Vinblastine + SCH-900776
|
DCNGRML
|
Vinblastine
|
Breast and ovarian cancer syndrome (Cell Line: UWB1289)
|
[2] |
|
Vinblastine + SCH-900776
|
DCT9U5R
|
Vinblastine
|
Breast carcinoma (Cell Line: OCUBM)
|
[2] |
|
Vinblastine + SCH-900776
|
DC16DFA
|
Vinblastine
|
Colon carcinoma (Cell Line: RKO)
|
[2] |
|
Vinblastine + SCH-900776
|
DCK0KWN
|
Vinblastine
|
Rectal adenocarcinoma (Cell Line: SW837)
|
[2] |
|
Vinorelbine + SCH-900776
|
DCVVVT6
|
Vinorelbine
|
Breast and ovarian cancer syndrome (Cell Line: UWB1289)
|
[2] |
|
Vinorelbine + SCH-900776
|
DCKAK5O
|
Vinorelbine
|
Breast carcinoma (Cell Line: OCUBM)
|
[2] |
|
Vinorelbine + SCH-900776
|
DC0T71Q
|
Vinorelbine
|
Carcinoma (Cell Line: OV90)
|
[2] |
|
Vinorelbine + SCH-900776
|
DC1NK5R
|
Vinorelbine
|
Colon carcinoma (Cell Line: RKO)
|
[2] |
|
Vinorelbine + SCH-900776
|
DCP1GTS
|
Vinorelbine
|
Rectal adenocarcinoma (Cell Line: SW837)
|
[2] |
|
Vinorelbine + SCH-900776
|
DCZ4121
|
Vinorelbine
|
Adenocarcinoma (Cell Line: NCIH520)
|
[3] |
|
Vinorelbine + SCH-900776
|
DCSD1JX
|
Vinorelbine
|
Adenocarcinoma (Cell Line: COLO320DM)
|
[3] |
|
Vinorelbine + SCH-900776
|
DC6BBKT
|
Vinorelbine
|
Adenocarcinoma (Cell Line: DLD1)
|
[3] |
|
Vinorelbine + SCH-900776
|
DCKE1HV
|
Vinorelbine
|
Adenocarcinoma (Cell Line: HCT116)
|
[3] |
|
Vinorelbine + SCH-900776
|
DC2DZNQ
|
Vinorelbine
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
Vinorelbine + SCH-900776
|
DCYTM57
|
Vinorelbine
|
Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2)
|
[3] |
|
Vinorelbine + SCH-900776
|
DC0Q81I
|
Vinorelbine
|
Germ cell tumour (Cell Line: PA1)
|
[3] |
|
Vinorelbine + SCH-900776
|
DCJVZLO
|
Vinorelbine
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
Vinorelbine + SCH-900776
|
DCQP0GP
|
Vinorelbine
|
Malignant melanoma (Cell Line: A375)
|
[3] |
|
Vinorelbine + SCH-900776
|
DCP90PO
|
Vinorelbine
|
Malignant melanoma (Cell Line: RPMI7951)
|
[3] |
|
Vinorelbine + SCH-900776
|
DCEEAI1
|
Vinorelbine
|
Malignant melanoma (Cell Line: SKMEL30)
|
[3] |
|
Vinorelbine + SCH-900776
|
DCC51UK
|
Vinorelbine
|
Ovarian endometrioid adenocarcinoma (Cell Line: A2780)
|
[3] |
|
Vinorelbine + SCH-900776
|
DCJI7KC
|
Vinorelbine
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[3] |
|
Vorinostat + SCH-900776
|
DCPW82Q
|
Vorinostat
|
Adenocarcinoma (Cell Line: CAOV3)
|
[4] |
|
Vorinostat + SCH-900776
|
DC2W6FY
|
Vorinostat
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[4] |
|
Vorinostat + SCH-900776
|
DC1RCMZ
|
Vorinostat
|
Adenocarcinoma (Cell Line: A427)
|
[4] |
|
Vorinostat + SCH-900776
|
DCTX1QX
|
Vorinostat
|
Adenocarcinoma (Cell Line: NCIH1650)
|
[4] |
|
Vorinostat + SCH-900776
|
DC8V0B1
|
Vorinostat
|
Adenocarcinoma (Cell Line: NCIH520)
|
[4] |
|
Vorinostat + SCH-900776
|
DCRPD5O
|
Vorinostat
|
Adenocarcinoma (Cell Line: COLO320DM)
|
[4] |
|
Vorinostat + SCH-900776
|
DCA2TST
|
Vorinostat
|
Adenocarcinoma (Cell Line: DLD1)
|
[4] |
|
Vorinostat + SCH-900776
|
DCWFQTN
|
Vorinostat
|
Adenocarcinoma (Cell Line: HCT116)
|
[4] |
|
Vorinostat + SCH-900776
|
DCQE95X
|
Vorinostat
|
Adenocarcinoma (Cell Line: HT29)
|
[4] |
|
Vorinostat + SCH-900776
|
DC820TV
|
Vorinostat
|
Amelanotic melanoma (Cell Line: A2058)
|
[4] |
|
Vorinostat + SCH-900776
|
DCHNK6M
|
Vorinostat
|
Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2)
|
[4] |
|
Vorinostat + SCH-900776
|
DCMWD7E
|
Vorinostat
|
Malignant melanoma (Cell Line: A375)
|
[4] |
|
Vorinostat + SCH-900776
|
DCW4CCF
|
Vorinostat
|
Malignant melanoma (Cell Line: HT144)
|
[4] |
|
Vorinostat + SCH-900776
|
DCIHE7C
|
Vorinostat
|
Malignant melanoma (Cell Line: RPMI7951)
|
[4] |
|
Vorinostat + SCH-900776
|
DCI75HV
|
Vorinostat
|
Malignant melanoma (Cell Line: SKMEL30)
|
[4] |
|
Vorinostat + SCH-900776
|
DC02JQN
|
Vorinostat
|
Mesothelioma (Cell Line: MSTO)
|
[4] |
|
Vorinostat + SCH-900776
|
DCJ6E0E
|
Vorinostat
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[4] |
|
Vorinostat + SCH-900776
|
DCX2BLO
|
Vorinostat
|
Prostate carcinoma (Cell Line: VCAP)
|
[4] |
|
Vorinostat + SCH-900776
|
DCT0KO1
|
Vorinostat
|
Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1)
|
[2] |
|
Vorinostat + SCH-900776
|
DCRFVOR
|
Vorinostat
|
Breast carcinoma (Cell Line: OCUBM)
|
[2] |
|
Vorinostat + SCH-900776
|
DCUQR9S
|
Vorinostat
|
Rectal adenocarcinoma (Cell Line: SW837)
|
[2] |
| ------------------------------------------------------------------------------------ |
|
|
|
|
